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Abstract 
Natural barriers prevent the inhalation and pulmonary penetration of 
particles larger than about 10 ýtm diameter. Therefore, in order to deliver 
powdered particles of drug directly to the lung the particle size must be less 
than 10 ýim. A particle diameter between 2 ýtm-5 ýtm is considered optimum 
for pulmonary delivery. Particles in this size range are inherently cohesive. 
This cohesive nature presents a problem for uniformed dosing due to the 
associated poor flow properties. Binary mixes of larger, pharmacologically 
inert particles with small particles of drug are often formulated to improve the 
flow characteristics. The aim of this work was to investigate the particle- 
particle interactions which occur in such binary mixes, and evaluate their 
effect upon pulmonary drug delivery. 
A comprehensive study was made into the roles of adhesion and cohesion 
within binary powder blends. The relationship between blend structure and 
pulmonary delivery was evaluated. Development of methodologies with the 
aim to quantify the interactive forces were reported. 
Materials were characterised using a variety of techniques. Particles of 
a-lactose monohydrate were mixed with the drug species nedocromil sodium, 
sodium cromoglycate or reporterol to prepare binary interactive mixes. 
Evaluation of the structure of the mixes identified complex interactive units 
as well as non-adhered drug aggregates. The formation of the non-adhering 
drug aggregates occurred regardless of the area of lactose surface available for 
adhesive interactions. 
Deposition of drug at the target site was evaluated in vitro using a 
multi-stage liquid impinger. Examination of the blend structure before and 
after inspiration of a dose, and evaluation of multi-stage liquid impinger data 
indicates that the majority of inspirable particles originate from the surface 
held drug aggregates. 
In order to investigate the apparent competition between adhesive and 
cohesive interactions novel methodologies were developed. A centrifuge 
technique and a cone penetration technique were developed in order to 
quantify the magnitude of the adhesive and cohesive forces respectively. 
Preparation of mixes which encouraged a random mix had a similar 
structure to the interactive mixes. Specific areas of the lactose surface appear 
to be preferential for adhesive interactions. Surface-held drug clusters are 
present in binary powder mixes, regardless of the method of preparation and 
drug load. 
This work has shown that adhesive interactions are responsible for 
maintaining the integrity of the interactive units, whereas the deposition of 
drug at the target site is cohesion dependent. 
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Asthma is a major cause of ill health in populations with a 
westernised culture. It has been estimated that the prevalence of 
asthma sufficiently severe to require regular medical supervision in 
England is from 4% to 6% in children and about 4% in adults [ 11. 
The diagnosis of asthma is best confirmed by evidence of variable 
or reversible airflow obstruction accompanying the symptoms of 
wheeze, cough, chest tightness and dyspnoea. These symptoms may be 
exacerbated by exposure to allergens such as house dust mites, animal 
dusts, pollen, fungal spores, passive smoking or other air pollution: 
More general factors such as exposure to cold air or stress may also 
trigger attacks. This hyper-reaction to non-specific stimuli causes 
bronchoconstriction. 
Asthma was the term used by Hippocrates in reference to the 
symptom of panting. It has been defined as "a clinical syndrome 
characterised by widespread airways obstruction, which is reversible 
either spontaneously or with treatment" [2]. Asthma is diagnosed by 
evidence of this reversible airflow obstruction which accompanies the 
symptoms of wheeze, cough, chest tightness and dyspnoea. 
The function of the airway is to allow air to come into close 
contact with blood in order that gaseous exchange can take place. The 
consistently branching structure of the airways can be described as a 
pulmonary tree. The trachea of the airways which bifurcates to form 
main bronchi, is analogous to the tree trunk. These airways divide to 
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form smaller bronchi that lead to individual lung lobes: three lobes on 
the right side and two on the left side. Within each lobe the bronchi 
undergo further bifurcation to form new generations of smaller calibre 
airways, the bronchioles. This process continues through the terminal 
bronchioles, the respiratory bronchioles, alveolar ducts, and terminates 
with the alveolar sacs. 
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Figure 1.1 Lung structure 
The airways which do not participate in gaseous exchange, from the 
trachea to the terminal bronchioles, are categorised as the conducting 
zone. The respiratory zone comprises of respiratory bronchioles, 
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alveolar ducts and alveolar sacs, which do participate in gaseous 
exchange. 
This structure forms an organ with a capacity of about 3000 mL 
after quiet, normal expiration, and 3400 mL upon normal inspiration. 
The total surface area at the level of the human alveolus is in the order 
of 140 M2 . There is a change in the total cross sectional area of the 
conducting airways, from 2.5 to 180 CM2 . This allows the rapid 
bulk 
flow of inspired air down to the terminal bronchiole. In contrast to this, 
within the respiratory zone the cross-sectional area increases, from 180 
to 10 000 cm 2. This results in a significant decrease in the velocity of 
airflow to such an extent that the flow velocity fails to exceed that of 
diffusing oxygen molecules. Of the 400 mL of air inspired by 
contraction of the inspiratory muscles the first 250 mL reaches the 
alveoli, the last 150 mL remains in the conducting airways when 
inspiration ceases and is exhaled as unchanged room air. The histology 
of each region of the pulmonary tree has a distinct effect on the 
functional aspects of the airway under physiological and 
pathophysiological conditions. 
Smooth muscle is separated from the epithelium by the lamina 
propria, a region of connective tissue containing nerves and blood 
vessels. The trachea is supported by incomplete cartilage rings. The 
smooth muscle supports the open ends of these rings, and therefore 
constitutes only a small proportion of this component of the airway. 
Further down the pulmonary tree, through the bronchi and 
bronchioles, the contribution of the smooth muscle to the airway wall 
increases to a point of completely encircling the airway. 
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The epithelium is a continuous sheet of cells lining the luminal 
surface of the airways. It comprises a variety of cell types. Throughout 
the conducting airways the luminal surface is lined with ciliated cells. 
Co-ordinated beating of these cilia propels a blanket of mucus towards 
the upper airway and pharynx where it is either swallowed or ejected. 
This mucus, secreted by goblet cells and mucus glands, fulfils three 
functions: (i) it protects the epithelia from becoming dehydrated; (ii) the 
water in the mucus is involved in saturation of the inhaled air; (iii) and 
it is involved in the protection of the airway from xenoparticles. This 
mucociliary escalator, the movement of the mucus up the pulmonary 
tree, is the method of clearing non-dissolving particles from the lung. 
Mast cells are distributed widely throughout the human 
respiratory tract. They are found in large numbers in the walls of the 
alveoli and airways. An appreciable number are found intercalcated 
between the epithelial cells and adjacent to the surface of the lumen. 
P -adrenergic receptors are also widely distributed in human 
airway and alveoli. The greatest density is seen on airway epithelium 
and alveolar walls, with a less dense distribution over airway and 
vascular smooth muscle. The receptors on airway and vascular smooth 
muscle, and on airway epithelium appear to be entirelyP2-receptors 
whilst P, -receptors account for 30 % of the P -receptors on the alveolar 
walls. 
The functional abnormalities characteristic of the airways of 
asthmatic patients include hyper-responsiveness to non-specific 
stimuli, reversible airflow limitation, and excess mucus production. 
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The hyper- responsiveness of the airways results in a narrowing of 
the airways by stimuli which does not cause a change in normal 
airways. It is unlikely that the responsiveness is related to an inherent 
abnormality of bronchial smooth muscle, which has normal reactivity 
in vitro. Damage to the epithelia increases responsiveness, which has 
led to the suggestion that a loss of putative epithehal -derived relaxation 
factor may be responsible. 
Airway narrowing results from the combined effects of mucosal 
inflammation and oedema, excessive intraluminal secretions and 
smooth muscle contraction. These effects are thought to be the 
consequence of an exaggerated inflam-matory process. 
The distribution of the mast cells throughout the airways results 
in these cells coming into immediate contact with an inhaled antigen. 
Degranulation of the mast cell results in the release of mediators. Some 
of these mediators cause rapid bronchoconstriction which characterises 
the acute phase of an asthma attack. Other mediators stimulate mucus 
production and recruit other inflammatory cells which are responsible 
for the delayed response. This late asthmatic response is complex and 
incompletely understood. It involves release of mediators from 
eosinophils which can produce epithelial damage, contribute to 
bronchoconstriction, increased vascular permeability, mucus secretion 
and further chemotaxis. 
Relief of the symptoms of asthma can be achieved by the 
administrationof P2-adrenoceptor agonists, mast cell stabilising drugs, 
and corticosteroids. Agonists of P2 -adrenoceptors are potent smooth 
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muscle relaxants which attenuate the bronchospasm induced by 
released mediators. They provide symptomatic relief where 
bronchoconstriction is the predominant cause of reduced airway 
calibre. Stabilisation of the mast cell membrane inhibits mediator 
release and prevents the ensuing inflammatory process. These type of 
drugs have no bronchodilator activity. Corticosteroids influence several 
immune system functions and thereby interfere with the inflammatory 
processes at several loci. Their main effect is to block late-onset 
asthmatic responses, and may prevent or reverse airway 
hypersensitivity. They may also modify 0 -adrenoreceptor populations 
and exert a permissive effect on P -adrenoreceptor function. 
Local drug delivery to the airways for the treatment of the 
symptoms of asthma has clear advantages over the oral or intravenous 
route. A faster onset of action and longer bronchodilation caused byP2 - 
adrenoceptor agonists occurs when comparing the effect of pulmonary 
delivery to that caused by similar intravenous, or much larger oral 
doses [3]. The low drug doses needed for the local route, due to the 
precise delivery of the drug at the site of action, leads to very little 
systemic absorption. This reduces the side effects associated with these 
drugs which occurs when they are distributed systemically. These 
include tremor and tachycardia associated with P2-adrenoceptor 
agonists and adrenal suppression associated with corticosteroids. It 
also offers a route for drug species which are active at sites in the 
airways but poorly adsorbed from the gastrointestinal tract, or readily 
eliminated, such as sodium cromoglycate. 
Page 6 
Chapter One 
In order to exert its pharmacological effect the drug must 
penetrate the pulmonary tree to the respiratory zone (Figure 1.1). The 
nature of the condition which causes high airflow resistance, and 
limitations of the inhalation device can result in as little as 10 % of the 
dose reaching the correct site within the lungs [4]. 
Delivery of drugs to active sites within the airways requires 
penetration of the drug into the pulmonary tree, overcoming the natural 
barriers to particles, to reach the distal regions of the lungs. In order to 
exert a pharmacological effect an inhaled drug particle must negotiate a 
route through the complex structure of the respiratory tract and 
impinge onto the lung surface in the alveolar region. Deposition of 
particles from the inhaled airstream onto the luminal mucus occurs by 
three principal phenomena: impaction, sedimentation and diffusion [5]. 
The mechanism of deposition is determined by the particle diameter. 
Deposition by impaction occurs when a particle has an inertia 
which makes it unable to change direction with the air flow. This 
occurs in the upper airways where the airstream changes direction 
entering the throat, and the upper airway bifurcations. This method 
removes particles with a diameter greater than 5 ym from the inspired 
air. Impaction deposition is enhanced when the air velocity is high, the 
airways are partially obstructed and by turbulent airflow in the trachea 
and major bronchi. 
Sedimentation describes the process of particles settling under 
the influence of gravity. Deposition by sedimentation is most likely to 
occur when the airflow is not turbulent and the air velocity is low. 
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For very small particles, under 5 ym, removal from the airstream 
occurs by Brownian motion. Random bombardment of the particles by 
gas molecules causes collision with the airway walls. 
Interception is a less important mechanism. Deposition by 
interception occurs when the diameter of a particle approaches the 
diameter of the airway. Particles large enough to deposit by interception 
in the lower airways often have sufficient mass to cause deposition by 
impaction or sedimentation in the upper airways. The role of 
interception, however, increases as a particle shape deviates from 
spherical [6]. 
The effect of the particle size on the location of its deposition can 
be described by Figure 1.2 [7]. 
0.01 0.1 1 
Aerodynamic Dian-)eter/Microns 
10 
Figure 1.2 Effect of particle size on deposition of a monodisperse 
aerosol (redrawn from [71) 
According to this model therefore, for maximum deposition in the 
respiratory zone particle size must be restricted between 2, um and 
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5, um. Particles larger than this are removed in the upper airways. 
Particles smaller than this may not be removed from the airstream and 
therefore will be exhaled with the expired air. 
Such a small size of drug which will penetrate into the pulmonary 
tree can be presented from a nebuliser, a pressurised aerosol or a dry 
powder inhaler. 
Pressurised aerosols deliver a fine spray of either drug solution or 
suspension. Most metered dose pressurised inhalers rely on the patient 
to release a dose from the aerosol in co-ordination with inspiration. 
This co-ordination is essential for optimum administration of the dose, 
but difficult to perform correctly. Recent studies have shown that at 
least 50 % of adults have difficulty using conventional MDls efficiently 
[8,91. Breath-actuated pressurised aerosols [101 and spacer devices 
have been developed in order to overcome this problem. 
Chlorofluorocarbon propellants are used extensively in the 
formulation of MDls as a dispersion medium for the drug, and more 
importantly, as the driving force for aerosolisation. With the implication 
that CFC compounds were partially responsible for the depletion of the 
ozone layer [III global production and use has declined. The Montreal 
Protocol on Substances That Deplete The Ozone Layer (1994) has 
reduced the use of CFCs in all of the signatory countries in all but 
essential uses. Although medicinal purposes are recognised as essential 
use alternative propellant systems are being developed [121 as are 
inhalation systems which do not require propellants. 
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Nebulisers produce clouds of liquid droplets in a gas. These 
droplets are solutions of the drug in aqueous solvents. To produce the 
cloud, a jet of compressed air is passed over the solution. This involves 
cumbersome equipment which is expensive and noisy. Treatment 
requires the patient to be stationary and talkes at least five minutes per 
dose. The dosing technique using a nebuliser involves normal breathing 
through a mouthpiece or a facemask. It can therefore be used for all 
ages and severities of the condition, and does not rely on co-ordination 
to inhale and deliver a dose. 
Dry powder inhalers are breath- actuated, propellant-free devices. 
The delivery of drug from the dose to the lungs is dependent upon the 
act of inspiration from the patient. It is influenced by the severity of the 
disease, the age of the patient, the dry powder formulation and the 
inhaler device. 
The pressure drop at the mouthpiece, created by the act of 
inspiration, causes the flow of air through the device. Turbulent airflow 
within the device is responsible for dispersing the powder mix from a 
static bed to a powder cloud. Turbulent airflow within the device 
inherently increases the resistance to airflow through the device. For 
any dry powder device the magnitude of this resistance is influenced by 
the tortousity of the airflow path and the minimum orifice diameter. 
The relationship between the airflow, resistance and pressure drop is 
shown in equation 1.1 [ 13 1. 
VXP-d- 






d- pressure drop 
specific resistance 
volumetric flow rate 
The resistance to airflow is dependent upon the design of the 
device, and is therefore device specific. The specific resistance (gradient 
of vIEP vs. Q) of several dry powder inhalers has been evaluated [ 13 
The results of which are shown in Table 1.1. 
Device Resistance (cmH20 1 
r2 /(L/ min) 
Rotahaler 0.040 
Spinhaler 0.051 




Table 1.1 Specific resistance of six types of dry powder inhalers 
The flow rate attained by a patient depends upon the air flow 
resistance of the device and the effort expended by the patient. The 
amount of work required by the patient to create the airflow is known 
as the inspiratory effort. This is directly proportional to the pressure 
drop [ 14]. Experimentally is has been shown that the energy input that 
can be achieved varies considerably between patients [ 15 1. 
In vitro determination has evaluated that for a specific dry powder 
inhaler, increasing the flow rate (equivalent to increasing the pressure 
drop or the inspiratory effort) increases the percentage of the dose 
which would reach the respiratory zone of the lungs [ 16 1. 
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The results from in vitro and in vivo deposition testing indicate 
only a small percentage of the dose from dry powder inhalers reaches 
the respiratory zone of the lungs. In vivo results have shown that the 
fraction of a dose from a dry powder inhaler found in the lung is in the 
range of 6.2 % to 16.4 % [171. 
The dose of drug from a dry powder inhaler is presented either as 
drug aggregates or a binary powder mix. Currently [ 181, Spinhaler TM 
and Turbohaler TM present doses as drug only formulations. The 
Rotahaler TM, Inhalator IngelheiMTM, Cyclohaler Tm and Diskhaler TM all 
present doses as a binary powder mix, usually with cc-lactose 
monohydrate crystals. As discussed previously the energy to create the 
turbulent airflow is provided by the patient. It is this airflow which 
causes dissociation of the particles in the dose, and creates a powder 
cloud containing single drug particles. This dissociation takes place in 
the inhaler device. 
The small fraction of the dose which is delivered to the 
respiratory zone indicates that the whole dose of active drug does not 
exist in the powder cloud as single particle entities. 
1.2 Scope of thesis 
Numerous investigations have been carried out into the effect of 
the testing conditions upon the performance of dry powder inhalers, 
both in vivo and in vitro. These include altering the environmental 
conditions [ 19,201, varying flow rates [ 19,21,221, investigating the 
effect of the inhaler design [ 171 and altering the formulation of the 
dry 
powder dose [231. Fundamental research, however, into the behaviour 
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of drug particles within the dose and the resultant dispersion 
characteristics are not so prevalent. The aim of this thesis was to 
investigate particle- particle interactions which take place within binaiy 
powder mixes which are used for inhalation therapy, and relate these to 
the delivery characteristics of the dose. 
Within a powder mix for inhalation therapy cohesive interactions 
occur between like particles (drug-drug), whilst adhesive interactions 
occur between dissimilar particles (drug-carrier). These interactions are 
responsible for the structure of the powder mix. In order to deliver drug 
particles into the pulmonary system during the delivery of the dose, the 
structure of the mix must disintegrate to produce isolated, airborne 
particles of drug. 
This investigation examined the degree of adhesive and cohesive 
interactions within powder mixes. The structure of the mix was related 
to the delivery characteristics, using in vitro inhalation test apparatus. 
Methodologies were developed with the aim of determining the 
magnitude of these inter-particle interactions. Such an understanding 
of the relationship between the interactions within the powder blend 
and the drug delivery from the blend would allow manipulation of the 







The aim of this chapter was to characterise the materials used 
throughout this work. This was done using a variety of analytical 
technologies in order to establish physical properties which may relate 
to the behaviour of the powders under investigation. 
2.2 Materials 
2.2.1 Nedocromil sodium 
Nedocromil sodium powder was used throughout this work. Five 
batches of the drug were characterised in order to establish any 
interbatch physical variation. 
Nedocromil sodium is a pharmacologically active drug used in 
inhalation therapy. It is a non-steroid agent which has anti- 
inflammatory properties when administered topically to the lung. 
In vivo, ex vivo and in vitro studies have shown that nedocromil sodium 
has beneficial effects on cellular, humoral and neuronal mechanisms 
thought to be involved in the inflammation of bronchial asthma [241. 
Nedocromil sodium is a yellow crystalline odourless powder 
which can exist as a number of hydrates. The trihydrate form is 
thermodynamically stable in ambient atmospheres, between 6.4 % and 
79.5 % relative humidity at 22 'C [251. The nedocromil sodium 
molecule has the chemical structure shown below. It has an anhydrous 
molecular weight of 415.3 Da. 
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Figure 2.2.1 Chemical structure of nedocromil sodium 
The following batches of nedocromil sodium were used in this work: 
Batch number Preparation Supplier 
Z403V Apex Milled Fisons, Holmes Chapel. 
ZBB9A Apex Milled Fisons, Holmes Chapel. 
3B I Apex Milled Fisons, Holmes Chapel. 
4BI Apex Milled Fisons, Holmes Chapel. 
5B I Apex Milled Fisons, Holmes Chapel. 
2001BI Apex Milled Fisons, Holmes Chapel. 
2002B I Apex Milled Fisons, Holmes Chapel. 
Table 2.2.1 Nedocromil sodium batch information 
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2.2.2 Sodium cromoglycate 
Sodium cromoglycate powder was used in the investigation of 
binary powder mixes and their performance in the multi-stage liquid 
impinger. 
Sodium cromoglycate is a pharmacologically active drug which is 
used in inhalation therapy. Its action inhibits the release from 
sensitised mast cells of mediators of the allergic reaction. In the lungs 
this inhibition of mediator release prevents both the immediate and the 
late asthmatic response to immunological stimuli. Sodium 
cromoglycate also prevents the bronchoconstriction caused by exercise, 
cold air and chemical irritants [241. 
Sodium cromoglycate is a white crystalline odourless powder. It 
is soluble in water up to approximately 5 %w/v. The sodium 
cromoglycate molecule has the chemical structure shown below. It has 
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Figure 2.2.2 Chemical structure of sodium cromoglycate 
The following batch of sodium cromoglycate was used in this work: 
Batch Number Preparation Supplier 
XC13CIAM150 j ApexMffled Fisons, Holmes Chapel. 




Samples of lactose were used throughout this work. Lactose is a 
white crystalline odourless powder and is pharmacologically inert [261. 
Lactose can exist in several different crystal forms, depending upon the 
method of its preparation. The crystal form used for this work was 
(x-lactose monohydrate. The chemical structure for the molecule is 









Figure 2.2.3 chemical structure of (x-lactose monohydrate 
The following batches of (x-lactose monohydrate were used in this work: 
Batch Number Grade Supplier 
022303 150 Mesh DMV 
Mean diameter 50, um 1 00%< 315, um. 
3217C 325 Mesh Fisons, 
Mean diameter 50 ym 1 oo%< 1 00, um. Loughborough. 
Table 2.2.3 Lactose batch information 
HOCH 
1 
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2.2.4 Reproterol 
Reproterol powder was used in the investigation of binary powder 
mixes and their performance in the multi-stage liquid impinger. 
Reproterol is a pharmacologically active drug used in inhalation 
therapy. The following batch of reproterol was used for this work. 
Batch Number Preparation Supplier 
092125 Apex milled Asta Medica AG 
Table 2.2.4 Reproterol batch information 
2.2.5 Budesonide 
A sample of budesonide powder was used in the particle sizing 
analysis as a contrast to samples prepared by milling techniques. 
Budesonide is a pharmacologically active drug which is used in 
inhalation therapy. The following batch of budesonide was used for this 
work. 
Batch Number Preparation Supplier 
_3189/MIMIOI 
1 Spray dried Astra, Sweden. 
Table 2.2.5 Budesonide batch information 
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2.2.6 Starch 1500 
A sample of Starch 1500 (pregelatinised maize starch) was used 
in the investigation of particle cohesion. The batch used for this work 
was: 
Batch Number Supplier 
1500 DM 486 Thornton & Ross 
Table 2.2.6 Starch 1500 batch information 
2.2.7 Kaolin 
A sample of Light Kaolin BY was used in the investigation of 
particle cohesion. The batch used for this work was 
Batch Number Supp lier 
18CL Thornton & Ross 
Table 2.2.7 Light Kaolin batch information 
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2.3 Scanning electron microscopy 
Scanning electron microscopy is a visual technique which, 
following production of a photomicrograph, can be used to observe 
particle shape, surface characteristics and to quantify particle size. A 
fine beam of electrons of medium energy scan across a gold coated 
sample in a series of parallel tracks. The electrons interact with the 
gold coat producing secondary electron emission, back scattered 
electrons, light or cathodoluminescence and X-rays [27]. Each of these 
signals can be detected and displayed on a cathode ray tube. These 
images are captured on a photomicrograph. 
2.3.1 Materials 
Scanning electron microscopy was carried out on the following 
samples: 
Sample Batch Number Figure number 
nedocromil sodium 3B 1 2.3.1 
nedocromil sodium 4B 1 2.3.2 
nedocromil sodium 5BI 2.3.3 
nedocromil sodium 2001BI 2.3.4 
nedocromil sodium 2002B 1 2.3.5 
nedocromil sodium 5B 1 2.3.6 
sodium cromoglycate XC13CLAM150 2.3.7 
reproterol 092125 2.3.8 
lactose 022303 2.3.9 
starch 1500 150ODM 486 2.3.10 
light kaolin 18CL 2.3.11 




Photomicrographs of the samples were produced using a Jeol 
JSM35 scanning electron microscope and an International Scientific 
Instruments DS130 scanning electron microscope. Gold coating of the 
samples was carried out using Blazer apparatus and Polaron co-stage 
sputter coater apparatus respectively. 
2.3.3 Method 
Samples were taken from stock bottles and dropped from a 
spatula onto a prepared adhesive disc. The disc was gently tapped to 
remove any particles not held by the adhesive. Sample preparation 
involved coating the particles with a thin layer of gold, under vacuum 
conditions. A total time of 5 minutes sputtering was sufficient to coat 
the particles with a layer of approximately 30 nm depth. 
2.3.4 Results 
2.3.4 a Nedocromil sodium 
Examples of the scanning electron micrographs taken of the 
samples of nedocromil sodium are reproduced in Figures 2.3.1 to 2.3.5. 
The crystal habit of the powder particles from all five samples is 
columnar. Each photomicrograph shows examples of particles in the 
size range between 0.5, um to 3, um. The surface of the larger particles 
exhibit deep pores and cracks. It is possible that these surface 
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irregularities are an artefact of the sample preparation procedure, or 
caused by the incident beam of electrons. There is some suggestion 
from the photomicrographs that particles much larger than 3 ym are 
present in the bulk powders. These can been seen in Figures 2.3.2 and 
2.3.5. The sample of batch 5B I taken for scanning electron microscopy, 
Figure 2.3.3, contains a higher proportion of particles towards the 
smaller end of the size range. 
Figure 2.3.1 Scanning electron micrograph of nedocromil sodium 
particles batch 3B 1. Picture no. 0664. 
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Figure 2.3.2 Scanning electron micrograph of nedocromil sodium 
particles batch 4B 1. Picture number 0663. 
Figure 2.3.3 Scanning electron micrograph of nedocromil sodium 
particles batch 5B 1. Picture number 0665. 
Page 23 
Chapter Two 
Figure 2.3.4 Scanning electron micrograph of nedocromil sodium 
particles batch 200 1B1. Picture number 0662. 
Figure 2.3.5 Scanning electron micrograph of nedocromil sodium 
particles batch 2002B 1. Picture number 066 1. 
Figure 2.3.6 Scanning electron micrograph of nedocromil. sodium 
particles batch 5B I. Picture number 2148. 
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2.3.4. b Sodium cromoglycate 
The sample of sodium cromoglycate investigated using scanning 
electron microscopy s ýiows the particles have a columnar structure. 
The size distribution of these particles appears similar to that of 
nedocromil sodium when comparing Figures 2.3.6. and 2.3.7. 
Figure 2.3.7 Scanning electron micrograph of sodium cromoglycate 
particles batch. Picture number 2155. 
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2.3.4. c Reproterol 
A photomicrograph of a sample of reproterol is reproduced in 
Figure 2.3.8. The sample contains particles up to 3 ym in length. The 
smaller particles appear isodiametric with a diameter of about 0.25, um. 
Figure 2.32.8 Scanning electron micrograph of reproterol particles. 
Picture number 0704. 
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2.3.4. d a-Lactose monohydrate 
A photomicrograph of a sample of lactose is reproduced in Figure 
2.3.9. The sample of lactose taken for scanning electron microscopy 
analysis shows the typical 'tomahawk'- shaped particles. These are in 
the size range 63 ym to 90 Aim. Sieving was used to size classify the 
particles, indicating that at least two dimensions of the particles are 
below 90 ym. Some particles present in the sample show a third 
dimension greater than 90, um. Very fine lactose particles can be seen 
adhering to the surface of larger particles. These surface-cohered fines 
are created during the screening procedure which is performed during 
the preparation of this grade of lactose. 
Figure 2.3.9 Scanning electron micrograph of lactose particles. 
Picture number 0693. 
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2.3.4. e Kaolin 
A photomicrograph of a sample of kaolin is reproduced in 
Figure 2.3.10. The sample of kaolin shows flaky particles. These range 
in size ftom approximately 0.5 ym to I um diameter. 
Figure 2.3.10 Scanning electron micrograph of kaolin particles. 
Picture number 2144 
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2.3.4. f Starch 1500 
A photomicrograph of a sample of the modified starch is 
reproduced in Figure 2.3.11. These irregularly shaped particles range 
from approximately 6.5, um to 53 ym diameter. 
Figure 2.3.11 Scanning electron micrograph of stairch particles. 
Picture number 2091 
2.3.5 Concluding c u mments 
All of the nedocromil sodium batches exhibit particles of a very 
(k. " e- 
similar size and shape. Therefore differences in behaviour Is not due to 
differences in these parameters. 
The size and morphology of particles of sodium cromoglycate are 
very similar to the particles of nedocromil sodium. Both drug samples 
were prepared by recrystallisation followed by milling. 
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2.4 Laser diffraction 
The laser diffraction size analysis technique is based on the 
calculation of particle size by analysis of diffraction patterns formed by 
low angle laser light scattering. A sample cell containing powder 
dispersed in a liquid in which it is not soluble, is held in the path of a 
laser beam. A diffraction pattern is formed when a powder particle is 
illuminated by the parallel beam of monochromatic coherent light. Size 
analysis can be carried out as the angle of diffraction is dependent 
upon the particle size. Small particles diffract the beam through greater 
angles than large particles. The detector of the diffracted light is split 
into a series of concentric rings, each one corresponding to the 
diffraction angles for a range of particle sizes. The intensity of light 
reaching each detector is proportional to the number of particles in a 
particular size range. 
2.4.1 Materials 
Laser diffraction size analysis was carried out on the following 
samples. 
Sample Batch Number 
Nedocromil sodium 5B I 
Sodium cromoglycate XC 13CLAA4150 
Reproterol 092125 
Budesonide 3189/Ml MIOI 




A coulter LS 130 apparatus was used for the determination of the 
particle size distribution of the samples. This apparatus is capable of 
calculating size distributions within the range 0.1 um to 800, um by 
measuring the diffraction angle and then applying Fraunhofer theory. 
2.4.3 Method 
A filtered saturated solution of each drug in analytical grade 
butanone containing 4.0 %w/v magnesium perchlorate was prepared 
as the suspending medium for nedocromil sodium, sodium 
cromoglycate and reproterol. Budesonide was suspended in a filtered 
saturated solution of the drug in HPLC grade water. This suspending 
medium was filtered through Whatman glass microfibre filters, type 
GF/B, pore size lym. 
A small amount of the powder sample was added to about 20 ml, 
of the suspending solution and subjected to sonication in an ultrasonic 
bath for 3 minutes. A few drops of this suspension were then added to 
the micro-volume diffraction cell which contained filtered suspending 
solution. Freshly filtered suspending solution was used as the blank. 




The frequency and cumulative size distributions of the samples 
are reproduced in Figures 2.4.1 to 2.4.4. 
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Figure 2.4.1 Particle size distribution for nedocromil sodium batch 5BI 
using laser diffraction analysis 
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Figure 2.4.5 Summary of particle size distributions for nedocromil 
sodium, sodium cromoglycate, reproterol and budesonide 
Page 37 
Chapter Two 
A summary of the derived equivalent particle sizes are shown in Table 
2.4-2. 







Nedocromil 3.75 4.43 3.36 
sodium 
Sodium 3.75 4.51 3.41 
cromoglycate 
Reproterol 2.32 2.99 2.28 
Budesonide 1.13 1.36 0.84 
Table 2.4.2 Derived mean particle sizes using laser diffraction particle 
size analysis 
2.4.5 Concluding comments 
The samples of nedocromil sodium, sodium cromoglycate and 
reproterol investigated using laser diffraction show a bi-modal size 
distribution. The modal diameters of the smaller diameter peaks are 
approximately lym for nedocromil sodium and sodium cromoglycate, 
and 1.4, um for reproterol. The modes of the larger diameter peaks are 
approximately 6, um for nedocromil sodium and sodium cromoglycate, 
and 4.5, um for reproterol. The sample of budesonide exhibits a single 
peak at approximately 1.2, um. 




2.5 Electrical stream sensing zone method 
The electrical stream sensing zone (ESZ or Coulter counter) 
technique is a method which determines the number and size of 
particles suspended in an electrolyte. The particles pass through a 
small orifice, on either side of which is immersed an electrode. The flow 
of electrical current between the electrodes submerged in the solution 
is measured by the electrical resistance across the aperture. When a 
particle passes through the orifice an amount of solution equal to the 
particle volume is displaced. This results in a change of electrical 
impedance, the amplitude of which is proportional to the volume of 
particles, and the number of which is equal to the number of particles. 
The parameter calculated is the diameter of a sphere causing an 
equivalent change in electrical resistance. 
2.5.1 Materials 
ESZ analysis was carried out using the following samples. 
Sample Batch Number 
Nedocromil sodium 5BI 
Sodium cromoglycate XC13CIAM150 
Reproterol 092125 
Budesonide 3189/Ml MIOI 




A Coulter Counter Multisizer was used for the determination of 
the particle size of the samples. A 30, um orifice tube was used which 
enabled accurate particle size determinations between 0.6, um and 
18 ym diameter. 
2.5.3 Method 
A filtered saturated solution of each drug in analytical grade 
butanone containing 4.0 % magnesium perchlorate was prepared as 
the suspending medium for nedocromil sodium, sodium cromoglycate 
and reproterol. The magnesium perchlorate is the electrolyte which 
conducts electricity in the solution. Budesonide was suspended in a 
filtered saturated solution of the drug in a sodium chloride solution. 
The suspending medium was filtered using a 0.05, um pore size filter. 
This solution was also used to prime the Coulter Counter. A small 
amount (approximately I mg) of the powder sample was added to about 
20 mL of this solution and subjected to sonication for 3 minutes. A few 
drops of the resulting suspension were added to a beaker containing 
100 mL of the electrolyte solution into which the orifice tube and 
electrodes were submerged. 
2.5.4 Results 
The frequency and cumulative size distributions of the samples 
are reproduced in Figures 2.5.1 to 2.5.4. 
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Figure 2.5.5 Summary of particle size distributions for nedocromil 
sodium, sodium cromoglycate, reproterol and budesonide 
A summary of the derived equivalent particle sizes are shown in Table 
2.5.2. 







Nedocromil 2.68 2.53 0.60 
sodium 
Sodium 2.08 2.20 0.60 
cromoglycate 
Reproterol 2.04 2.02 0.42 
Budesonide 1.54 1.91 0.78 
Table 2.5.2 Derived mean particle sizes using ESZ particle size analysis 
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2.5.5 Concluding comments 
The samples of nedocromil sodium, sodium cromoglycate and 
reproterol investigated using electrical zone sensing show a size 
distribution between <I um and 10, um. The few very large particle 
sizes determined for budesonide reflect the possible aggregation of the 
small spray dried particles in the suspension. 
2.6 Particle size discussion 
The size of a spherical homogeneous particle can be uniquely 
defined by its diameter. Derived equivalent diameters are determined 
by relating a size dependent property of a particle to a linear dimension. 
The equivalent spherical diameter is the most widely determined 
diameter. 
Laser diffraction sizing determines the diameter of a sphere 
which causes the equivalent scattering of light through a defined angle 
as the sample particle. Electrical zone sensing analysis determines the 
diameter of a sphere which causes an equivalent change in electrical 
resistance as the sample particle. 
For irregular shaped particles the size determination method is 
often dependent upon the method of measurement. The evaluation of 
particle shape, carried out by scanning electron microscopy (Section 
2.3) showed that the samples of nedocromil sodium, sodium 
cromoglycate, reproterol and budesonide are non-spherical. This is 
reflected in the variation of particle size determination between the 
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laser diffraction and electrical zone sensing methods. However, the 
particle size distributions of the samples relative to each other reniaill 
constant, regardless of the analytical method. 
Bi-modal size distributions are observed for the samples of 
nedocromil sodium, sodium cromoglycate and reproterol. This type of 
size distribution is typical of powder samples which have undergone a 
process of particle size reduction. Differences in the fracture behaviour 
of coarse and fine particles leads to a size reduced bi-modal Population 
of particles from an approximately normal initial size distribution. This 
can be described by Figure 2.6.1. All of the three samples whicil 
showed this bi-modal distribution had undergone particle size 
reduction in an Apex Mill. 
Particle diameter - 
Figure 2.6.1 Transformation of approximate normal particle size 
distribution into finer bi-modal distribution following particle size 
reduction [281 
The particle size distribution of budesonide was also determined. 
This was carried out in order to verify that the distribution of size 
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exhibited by nedocromil sodium, sodium cromoglycate and reproterol 
was not an artefact of the analysis techniques. Budesonide particles 
had been prepared by spray drying. No particle size reduction of the 
spray dried product had been performed. This produced the log-normal 
distribution as expected, confirming that the previous distributions 
were not influenced by the sizing procedure. 
The summary of the particle size distributions evaluated using 
laser diffraction and electrical zone sensing are reproduced in Table 
2.6.1. 
Laser diffraction Electrical zone sensing 
Sample Arithmetic Standard Geometric Standard 
mean deviation mean deviation 
volume CUM) volume (jum) 
diameter diameter 
CUM) CUM) 
Nedocromil 4.43 3.36 2.53 0.60 
sodium 
Sodium 4.51 3.41 2.20 0.60 
cromogtycate 
Reproterol 2.99 2.28 2.02 0.42 
Budesonide 1.36 0.84 1.91 0.78 
Table 2.6.1 Particle sizing summary 
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2.7 Mass loss on drying 
In order to quantify the mass of water released by nedocromil 
sodium (batches 3131,4BI, 5131,200IBI, 2002131) and sodium 
cromoglycate (batch XC13 CIA M150) during dehydration the following 
procedure was carried out. 
2.7.1 Method 
About Ig of drug sample was weighed accurately and placed into 
a glass heating vessel with the lid positioned to allow air circulation. 
The vessel was then placed into the oven alongside a blank containing 
no sample. The samples were heated to 200' C. The samples were held 
at this temperature for two hours. The vessels were then transferred to 
a desiccator through which nitrogen was flowing. After an hour in these 
conditions the lids were replaced securely and the samples weighed 
again. 
2.7.2 Results 
The results from the experimental provides the mass lost per 
gram of hydrated sample. The percentage initial moisture content 
(M. C. ) can be calculated using the formula 
(mass of hydrated sample) - (mass of anhydrous sample) x 100 = M. C. 




The corresponding number of moles of water associated with each mole 








sodium anhydroue "z 415 Da 
MWH20 = 18 Da 
Table 2.7.1 shows the calculated values for the five nedocromil 
sodium batches. 





No. of moles of 
water per mole 
of drug sample 
3B 1 0.043 4.49 1.0 
4B 1 0.045 4.71 1.1 
5B 1 0.088 9.65 2.2 
2001BI 0.080 8.70 2.0 
2002B 1 0.052 5.49 1.3 
Table 2.7.1 Summary of the water content of five nedocromil sodium 
batches 
Using the same method, the moisture content results for the 
sample of sodium cromoglycate was found to be 5.71 % [291 which 




Reproterol and budesonide exhibited negligible weight loss [291 
indicating that the crystals were not hydrated. 
2.7.3 Discussion 
At ambient temperature and relative humidity nedocromil sodium 
exists as a trihydrate, as described in Figure 2.7.1. The mass lost from 
the nedocromil. sodium samples during the drying experiment does not 
correspond to the loss expected from a trihydrate form of the crystal. 
Two types of bound water are held in the nedocromil molecular crystal 
and when heated, leave it in different ways. The trihydrate form is 
converted to a monohydrate at temperatures ;? t 70' C. This corresponds 
to the "loosely bound" water which is hydrogen bonded [301. This water 
is lost anisotropically along the crystal axis. During the second 
dehydration event "tightly bound" water molecules, which are bonded 
to the carboxylic acid groups [301, are lost. This results in 
fragmentation of the crystal structure [251. Visual observation of the 
samples after they had been heated for the predetermined time revealed 
yellow crystals similar to those observed before heating, rather than 
darker brown crystals. This indicates that after heating in the oven and 
cooling under nitrogen, the nedocromil sodium crystals were not fully 
dehydrated. Therefore the corresponding three moles of water were not 
lost. It is suggested that batches 5B I and 200 1BI more readily lose the 
"loosely bound" water compared with the remaining three batches. 
Alternatively batches 5B I and 2001B I may have more adsorbed water 





















Figure 2.7.1 Hydrated states of nedocron-ffl sodium [301 
Sodium cromoglycate does not exist as a fixed hydrate. The 
crystals can absorb or lose water as a continuous series of interstitial 
solid solutions, with water as the interstitial component. The amount of 
water absorbed, or lost, is proportional to the relative humidity 
environment of the crystals. Between 30-70 % relative humidity at 
ambient atmosphere the interstitial water approaches five to six 
molecules per molecule of sodium cromoglycate [311. This corresponds 
to the moisture content determined for sodium cromoglycate. 
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2.8 Differential Scanning Calorimetry 
Differential scanning calorimetry (DSC) is a method of thermal 
analysis. It can be used to identify dehydration events which occur in a 
solid samples as its temperature is increased. 
Dehydration is an energy requiring (endothermic) transition. This 
can be detected and quantified by the DSC apparatus. A sample is 
loaded into a small aluminiurn pan. An empty pan is used as a 
reference. A constantan disc transfers heat to the reference sample and 
the sample for analysis, which are positioned within the oven chamber 
of the apparatus. The sample is heated at a constant rate by heat 
transfer from the constantan disc, through the sample pan to the 
sample. A thermocouple detects any differential heat flow at the sample 
and reference positions. The power associated with an endothermic 
transition is recorded as a peak on a plot of AH against temperature for 
the system. 
2.8.1 Materials 
Differential scanning calorimetry was used to identify 
dehydration events in the following samples. 
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Sample Batch Number 
nedocromil sodium 3B I 
nedocromil sodium 4B I 
nedocromil sodium 5B I 
nedocromil sodium 2001BI 
nedocromil sodium 2002B I 
sodium cromoglycate XC13CLA-MI50 
jactose 022303 
Table 2.8.1 Differential scanning calorimetry sample summary 
Nedocromil sodium samples were prepared for analysis as shown 
in Table 2.8.2 
Sample preparation Batch Number 
From ambient conditions 3BI, 4BI, 5BI, 2001BI, 2002BI 
Stored at 60 % relative humidity 4BI, 2002BI 
for 14 days 
_ 
Heated to 240 'C, allowed to cool 
to ambient temperature in a 4B I 
nitrogen environment 
_ 
Heated to 240 'C, allowed to cool 
to ambient temperature in the 4B I 
laboratory environment 
Table 2.8.2 Preparation of nedocromil sodium samples tested using 
differential scanning calorimetry 
Interactive binary mixes of nedocromil sodium with a-lactose 
monohydrate, and sodium cromoglycate with cc-lactose monohydrate 
(as prepared in Chapter Three) were also investigated using differential 
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scanning calorimetry. The mixes investigated are presented in 
Table 2.8.3. 
mix Drug concentration in mix 
Nedocromil sodium (5B 1) with 2% w/w 
(x-lactose monohydrate 
Sodium cromoglycate with 2% w/w 
a-lactose monohydrate 
Table 2.8.3 Powder blends analysed using differential scanning 
calorimetry 
2.8.2 Apparatus 
A DuPont series 99 thermal analyser and 910 differential 
scanning calorimeter was used to determine the DSC profiles of the 
samples. 
2.8.3 Method 
A precisely known mass, about 4 mg, of sample was weighed into 
the aluminium sample cap. This was placed in the oven chamber of the 
apparatus alongside the reference cap. A gentle stream of helium 
flowed through the oven chamber in order to create an inert 





2.8.4. a Nedocromil sodium 
The DSC plots are reproduced in Figures 2.8.1 to 2.8.5. 
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Figure 2.8.1 DSC scan for nedocromil sodium batch 3B I from ambient 
conditions 
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DSC VAN: NEDOCROMIL 4B1 
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Figure 2.8.2 DSC scan for nedocromil sodium batch 4B I from ambient 
conditions 
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Figure 2.8.3 DSC scan for nedocromil sodium batch 5B I from ambient 
conditions 
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DSC VAN: NEDOCROMIL 2001 B1 
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Figure 2.8.4 DSC scan for nedocromil sodium batch 200 1BI from 
ambient conditions 
DSC VAN: NEDOCROMIL 2002 B1 25 Feb 1993 14: 30: 48 
40 60 00 100 120 140 160 180 200 220 240 
m 
E 




' Lin. OpwarAing 1 . 999961 
cu 
TEMP. (*C) -) 
Figure 2.8.5 DSC scan for nedocromil sodium batch 2002B I from 
ambient conditions 
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0 2. . 4. a. i Results 
The DSC plot identifies two endothermic events. These lie at 
65 T and 160 T. The temperature and extent of these peaks are 
consistent for each sample of nedocromil sodium. 
2.8.4. a. ii Discussion 
As observed by Khankari [251, the dehydration of nedocromil 
sodium crystals occurs in two steps. In the first the "loosely bound" 
water is lost. This is followed by the loss of the "tightly bound" water 
and subsequent fragmentation of the crystal. The two peaks observed 
in the DSC plots of nedocromil sodium correspond to these two 
dehydration steps. Visual inspection of the sample after heating to 
250 'C revealed the sample had changed in appearance from yellow to 
dark brown. 
This differential scanning calorimetry method showed no 
difference in behaviour between the five batches of nedocromil sodium. 
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2.8.4. a. iii Elevated humidity 
The plots obtained from the samples of nedocromil sodium stored 
at 60 % relative humidity for 14 days are reproduced in Figures 2.8.6 
and 2.8.7. 
DSC VRN: NEDOCROMIL 4BI 
40 Go 80 100 
II Mar 1993 It. -49-55 




TEMP. (10 -) 
I 
Figure 2.8.6 DSC scan for nedocromil sodium batch 4B I stored at 60 % 
relative humidity 
USC VRN: NEDOCROMIL 2002H1 
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Figure 2.8.7 DSC scan for nedocromil sodium batch 2002B I stored at 
60 % relative humidity 
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The DSC plot identifies two endothermic reactions. These lie at 
65 *C and 160 'C. These peaks are consistent for both samples of 
nedocromil sodium which had been stored at an elevated humidity. 
2.8.4. a. iv Concluding comment 
No difference between the DSC plots is observed due to this 
sample preparation. This suggests that there is no alteration in the 
distribution of water in the molecular crystal due to the 60 % relative 
humidity conditions. Therefore the stock samples are confirmed as the 
trihydrate form of the crystal. 
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2.8.4. a. v. Moisture re-uptake 
The efficiency of moisture re-uptake by nedocromil sodium 
crystals was studied by heating the samples to 240 T in a gentle 
stream of helium. The samples were then allowed to cool either in a 
steady flow of nitrogen, or in the laboratory environment (22 'C, 67 % 
R. M. The resultant DSC traces are reproduced in Figures 2.8.8 and 
2.8.9. 
OK VRN: HED0M01tIL 4Bi Iß M., 1993 14: 45: 12 
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Figure 2.8.8 DSC scan for nedocromil sodium batch 4B I heated to 
240 'C, cooled in nitrogen 
USC VRN: WJIOCRORL 4BI II hu ISM 12: 54: 33 
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Figure 2.8.9 DSC scan for nedocromil sodium batch 4B I heated to 
240 'C, cooled in laboratory conditions 
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2.8.4. a. vi. Results 
The sample cooled in the absence of moisture (Figure 2.8.8) 
reveals no endothermic transitions, as expected. When cooled in 
ambient conditions the DSC trace shows the typical two dehydration 
peaks. 
2.8.4. a. vii Concluding comment 
These results indicate that 30 minutes in an ambient 
environment is sufficient time for a degree of rehydration of the 
molecular crystal to take place. This suggests that non-reversible 
fragmentation of the crystal has not taken place. 
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2.8.4. b Sodium cromoglycate 
The DSC plot identifies a single endothermic event. This 
corresponds to dehydration of the removal of adsorbed water associated 
with the crystal. 
80 100 120 
Opwarmsnelheýd lp *C/MIN 
ý; Lin. Opwarming \ . 99P96 
S 
140 160 180 
TEMP. (10 -) 
Figure 2.8.10 DSC scan for sodium cromoglycate from ambient 
conditions 
3 Sep 1993 14: 39: 43 
200 220 240 
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2.8.4. c a-lactose monohydrate 
The DSC plot obtained for lactose was typical of those exhibited 
by the a-lactose monohydrate form of the crystal [321. The endothermic 
transition at 140 T corresponds to dehydration of the product. A 
melting endotherm is present at 2 10 T. 
DSC VRN: LRC 3 Sep 1993 11: 43: 03 
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Figure 2.8.11 DSC scan for lactose from ambient conditions 
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2.8.4. d Drug-lactose mixes 
The DSC plots recorded for these samples are reproduced in 
figures 2.8-12 and 2.8.13. These show a combination of the traces from 
the components in the powder mix. There appears to be no interactions 
affecting the transition stages from either component, in either mix. 
DSC VM: SBILLRC 2% 3 Sýp 1553 10: 45: 43 
48 so 00 loa 120 148 160 lea zw 2zo 240 
I -, 
. 995562 
Figure 2.8.12 DSC scan for nedocromil sodium batch 5B 12 %w/w mix 
with lactose 
w 
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40 so 00 100 120 140 160 190 200 220 240 
Opwarmsnelhold 10 *C/MIN 
Lin. Opwarming . 9999GG 
r 
L=i 
TEMP. (10 -) 
Figure 2.8.13 DSC scan for sodium cromoglycate 2 %w/w mix with 
lactose 
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2.8.5 Concluding comments 
Dehydration events, identified by differential scanning 
calorimetry confirm the materials used for this work behave in the 
manner expected for nedocromil sodium trihydrate, sodium 
cromoglycate and cc-lactose monohydrate. 
All batches of nedocromil behaved in an identical way, suggesting 
that difference in behaviour as an inhalation dosage form is not due to 





The technique of pycnometry determines the volume of 
irregularly shaped particles, the results of which are used to calculate 
true density. The sample volume is determined by displacement of gas 
from a sample chamber of accurately known dimensions, due to the 
sample. The pycnometer apparatus consists of two gas chambers: a 
sample chamber and an expansion chamber. The powder sample is 
placed into the sample chamber and sealed into the apparatus. Helium 
gas is used to charge this chamber, the small molecules of gas are able 
to penetrate pores and surface irregularities of the sample. The 
chamber is raised to an elevated pressure. The volume occupied by the 
gas is then increased by a precisely known expansion volume by 
opening a valve connecting the sample chamber to the expansion 
chamber. The new lower pressure associated with this increase in 
volume is inversely proportional to the volume of gas in the sample 
chamber under pressure. Powder samples which displace a large 
volume of helium from the sample chamber., therefore, are associated 




Sample Batch Number 
nedocromil sodium 3B I 
nedocromil sodium 4B I 
nedocromil sodium 5B I 
nedocromil sodium 200IB1 
nedocromil sodium 2002B I 
sodium cromoglycate XC13CIAM150 
reproterol 092125 
budesonide 3189/Ml MIOI 
lactose 022303 
Table 2.9.1 True particle density determination sample summary 
2.9.2 Apparatus 
A Quantachrome Multivolume Helium Pycnometer, using a large 
volume sample cell was used to determine the volume of the samples. 
Helium was used as the purge gas. 
2.9.3 Method 
Prior to use the instrument was calibrated by determining the 
volume of a precision ball bearing, which by design occupied the 
maximum possible volume of the sample cup. Thorough cleaning of the 
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apparatus ensured that the sample chamber and sample cup were free 
from particulate contamination. 
The sample cup was loaded to two thirds of its capacity with the 
sample and placed in the sample chamber. The sample chamber was 
purged with Helium gas three times prior to taking readings. This was 
to ensure that any residual air or moisture which may have been 
present on the sample was displaced. 
The sample chamber was then raised to a Helium gas pressure of 
approximately 19.5 ± 0.2 psi (equivalent to approximately 134 kPa). 
allowed to equilibrate and the pressure recorded (PI). The valve 
connecting the sample and expansion chambers was opened. The 
Helium gas then expanded into the expansion chamber, was allowed to 
equilibrate, and the expansion pressure (P2) recorded. The mass of the 
sample and empty sample cup were recorded at the end of testing. This 
ensured that the mass recorded was a reflection of the true mass of the 
sample, free of air and moisture vapour. 
2.9.4 Results 








where Vsarnp = sample volume 
Veell 
(equation 2.9.1) 
= empty volume of the sample cell with the empty 




Vexp = expansion volume 
PI = charge pressure (psi) 
P2 
= expansion pressure (psi) 
Calculation of sample density follows the evaluation of the 
sample volume. The density of a material is, by definition, the mass per 




gross mass - cup mass 
V samp 
where Psamp = sample density 
Msamp = sample mass 
VS2MP = sample volume 
(equation. 2.9.2) 
The following densities for the powder samples were determined: 
Sample Hydrated Sample Hydrated 





3B 1 1.571 Sodium 
4B 1 1.580 cromoglycate 1.590 
5B 1 1.583 Reproterol 1.445 
2001BI 1.558 Budesonide 1.264 
2002B 1 1.572 Lactose 1.533 
Table 2.9.2 Sample densities evaluated using helium pycnometry 
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2.9.4 Concluding comments 
Statistical analysis using one-way analysis of variance (P<0.05) 
shows no significant difference between the evaluated density values for 
nedocronffl sodium samples. 
The density values derived for the samples of nedocromil sodium 
and sodium cromoglycate are significantly different (P<0.05). 
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10 BET Analysis 
BET analysis is a gas adsorption technique which can be used to 
quantify particle surface area. In this context, adsorption is the 
phenomenon which occurs when gas molecules impinge upon a solid 
and reside on the surface for a finite time. The amount of gas adsorbed 
depends upon the nature of the gas (adsorbate) and the solid 
(adsorbent), and the pressure at which adsorption takes place. 
The derivation of surface area from gas adsorption data assumes 
that the total amount of gas adsorbed will form a complete monolayer 
coverage of the powder particles. However, as the solid surface becomes 
progressively coated, the probability increases that a gas molecule will 
strike and be adsorbed onto a previously bound molecule. The 
Brunauer, Emmett and Teller (BET) theory [331 enables an 
experimental determination of the number of gas molecules required to 
form a monolayer, despite the fact that exactly one monomolecular 
layer is never actually formed. 
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The BET equation is expressed below: 
+ (equation. 2.10.1) V(P, /P - 1) vmc vmc PO 
(P) 
where P= partial pressure of the adsorbate 
PO = saturated vapour pressure of the ads6rbate 
V= volume of adsorbed gas 
VM = volume of adsorbed gas in a completed monolayer 
c =constant= e where 9, = heat of adsorption 
of the first layer 
QL= heat of liquefaction 
of the bullk liquid 
The determination of surface area from the BET theory follows 
the construction of a plot of VV(PO/P - 1) against P/Po. This yields a 
straight line with a gradient (c - 1)/V. c and intercept I/V. c. A value 
for Vm can then be determined, by solving equation 2.10.2 
VM = V(gradient + intercept). (equation. 2.10.2) 
Single point BET analysis can be used as an alternative to 
construction of the above plot. As the name suggests a single point of 
data is evaluated rather than a complete isotherm. The errors 
introduced by this method are very small [33]. This method is possible 
using the following approximation of the BET equation. 
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For high values of c the intercept is small compared to the 
gradient, which can be considered negligible. The BET equation 





) (equation. 2.10.3) 
The evaluation of V. . the volume of adsorbed gas required to form a 
monolayer, leads to the determination of particle surface area using a 
working formula such as equation 2.10.4 (see section 2.10.4). 
2.10.1 Materials 
Sample Batch Number 
Nedocrornil sodium 5B I 
Nedocromil sodium 2001BI 
Lactose 022303 
Table 2.10.1 Surface area determination sample summary 
Samples of nedocromil sodium for which the extreme values of 
density were derived were analysed using gas adsorption. The samples 
were prepared for analysis as shown in Table 2.10.2. 
Sample preparation Batch Number 
Ambient conditions 5BI, 2001BI 
60 % relative humidity 5BI, 2001BI 
Heated to 80 'C under helium 
for 12 hours 
5BI, 2001BI 




A Quantachrome BET apparatus was used to determine the 
surface area of the samples. Nitrogen gas was used as the adsorbate 
with helium as the carrier. 
2.10.3 Method 
The single point BET method used determined the amount of gas 
adsorbed by the sample volumetrically. In this method the sample is 
situated in a steadily flowing stream of a mixture of two gasses. One is 
the adsorbate and the other the 'carrier' gas. An environment is created 
in which the adsorbate is removed from the gas mix and retained on 
the sample surface. This is followed by a change in conditions such 
that the adsorbate is no longer associated with the sample. The 
desorption of the adsorbate causes an increase in pressure of the gas 
mix flowing from the sample. The magnitude of the pressure increase is 
translated to a deflection from normal on a chart recorder. Prior to use 
the recorder was calibrated by injecting a precise volume of adsorbate 
to the stream of gas flowing from the sample. The deflection caused by 
the pressure increase due to the calibration volume was recorded. A 
calibration injection producing a similar deflection as that caused by 
release of adsorbate was also carried out after every adsorbate 
determination. 
A known mass of sample was measured into the sample tube of 
the apparatus. The mix of the nitrogen and helium gasses was set so 
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that 15 % of the total pressure of the gas mix was due to nitrogen. At a 
given pressure the quantity of physically adsorbed gas increases with a 
decreasing temperature. The adsorption measurements were therefore 
carried out at the temperature of liquid nitrogen. A vessel containing 
liquid nitrogen was positioned such that the tube containing the 
sample was submerged fufly. This was held in position until nitrogen 
adsorption was completed and the total gas pressure returned to the 
normal. The vessel containing liquid nitrogen was then replaced by a 
beaker containing water at ambient temperature. The pressure increase 
of the gas mix was recorded on the chart recorder. A calibration volume 




Single point BET analyses can be carried out to determine the 
surface area of the powder sample. The use of nitrogen as the 
adsorbate at liquid nitrogen temperatures results in a high value for c, 
the constant in the BET equation [341. Therefore equation 2.10.3 can 
be applied. 







Pa (equation. 2.10.4) 
where St = sample surface area 
(M2) 
A= signal height 
Ac = calibration height 
VC = calibration volume 
(M2) 
P= partial pressure of adsorbate (Pa) 
PO = saturated pressure of adsorbate (Pa) 
N= Avogadro's number (mol 
Acs = adsorbate molecule cross-sectional area 
(M2) 
Pa 
= ambient pressure (Pa) 
R= molar gas constant (J mol-'K-' 
T= ambient temperature (K) 
Samples of nedocromil sodium were used from ambient 
conditions, from conditioning at 60 % relative humidity, and from 
conditioning overnight in a stream of helium being heated to 80 OC. 
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The single point BET analysis derived the following values for the 
surface area of the samples. 
Drug sample and storage Speciflc surface area (m2g-') 
conditions 
Nedocromil sodium, ambient 8.46 (SD±O . 13) 
conditions batch 5B I 
Nedocromil sodium, 60 % relative 4.65 (SD±0 . 09) 
humidity batch 5B I 
Nedocromil sodium, heated to 
80 'C under helium for 12 hours 8.88 (SD±0 . 20) 
batch 5B I 
Nedocromil sodium, ambient 8.52 (SD±0 . 06) 
conditions batch 2001BI 
Nedocromil sodium, 60 % relative 4.88 (SD±O . 19) 
humidity batch 2001B I 
Nedocromil sodium, heated to 9.05 (SD±O . 11) 
80 'C under helium for 12 hours 
batch 2001B I 
Lactose, ambient conditions 0.16 (SD±0 . 004) 
Table 2.10.3 Surface area values 
2.10.5 Concluding comments 
Statistical analysis shows no significant difference in specific 
surface area between the two drug batches when stored in laboratory 
conditions, and when heated under helium (P<0.05). The values derived 




2.11 Drug assay 
Ultraviolet spectroscopy was used as the assay method for the 
aqueous solutions of nedocromil sodium, sodium cromoglycate and 
reproterol. It was necessary to determine the compliance of these drug 
solutions with the Beer-Lambert equation. 
The ultraviolet and visible spectra of organic compounds are 
associated with transitions between electronic energy levels. Excitation 
of electrons above 200 nm from p- and d- orbitals, and iT-orbitals and 
iT-conjugated systems, give rise to spectra which is easily measured. 
The energy of electronic excitation is related to wavelength by the 
following: 
E(kJ/mol) = 




The energy of electronic excitation for each drug compound can 
be calculated after determination of the )k'max wavelength for each 
solution. This was done by performing a scan over the wavelength 
range 300-220 nm. The energy of excitation for nedocromil sodium, 
sodium cromoglycate and reproterol was found to be 469 kJ, 365 kJ 
and 433 kJ, respectively. 
Two empirical rules have been formulated to describe adsorption 
intensity. Lambert's Law states that the fraction of incident light 
absorbed is independent of the intensity of the source. Beer's Law 
states that the absorption is proportional to the number of absorbing 
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molecules. The combined Beer-Lambert equation is shown in equation 
(2.9.2). i. e. Beer-Lambert Law. 
loglo (1(, /I) =E cl =A 
where 1() = intensity of incident light 
I= intensity of transmitted light 
(equation 2.11.2) 
e =molar extinction coefficient 
(dM3MOI-ICM-1) 
c= solution concentration (mol dm-3) 
I= path length (cm) 
A= absorbance 
The factor loglo (10/1) is therefore proportional to the amount of 
absorbing material present in the sample. The absorbance, also known 
as optical density, is related to the transmittance (T) as shown in 
equation 2.11.3 
I/T =E cl (equation 2.11.3) 
Since E-= and I are constant, a linear relationship between 
absorbance and concentration of drug indicates compliance of the 
compound with the Beer-Lambert Law. 
2.11.1 Method 
Solutions were prepared of the sample drug in deionised water. 
UN spectroscopy was carried out using a Philips PU 8729 UV/Vis 




Figures 2.11.1,2.11.2, and 2.11.3 show the Beer-Lambert plots 
for nedocromil sodium, sodium cromoglycate and reproterol 
respectively. 
In order to ascertain the effect of the presence of lactose on the 
absorption spectra, solutions of lactose were assayed at the values 
for each compound. No interference was observed due to the presence 
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Figure 2.11.1 Beer-Lambert plot for nedocromil sodium in deionised 
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Figure 2.11.2 Beer-Lambert plot for sodium cromoglycate in deionised 
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2.11.3 Summary of standard curve equations 
Drug species Wavelength of 




Nedocromil sodium 254 nm Conc(mg/mL) = 
Abs - 0.012 
77.009 
Sodium cromoglycate 326 nm Conc(mg/mL) = 
Abs - 0.001 
15.103 
Reproterol 275 nm /mL) = 
Abs - 0.004 Conc(m g 24.937 




Particle characterisation was carried out for the five batches of 
the drug nedocromil sodium. No significant physical differences were 
detected between the batches using these testing procedures. However, 
interbatch variation has been observed with respect to the performance 
of the drug with respect to blending with lactose and drug release 
evaluated using a multi-stage liquid impinger. This variation may be 
due to the possible introduction of crystalline disorder onto particle 
surfaces due to the size reduction process. 
The particles of nedocromil sodium have been subjected to Apex 
milling in order to achieve the small size fraction required for 
pulmonary delivery. Gross changes in the physical states of raw 
materials have been observed due to particle size reduction [35-38]. The 
energy input during communition can impart amorphous character to 
once highly crystalline particles. Often these amorphous regions 
constitute only a small percent of the total mass. Because these regions 
are very small they are beyond the limits of detection by traditional 
analytical methodologies [391. However, these small areas of 
amorphous material can have profound physical effects [401. 
Aggregation of small particles in suspension as a response to the 
processing techniques used to prepare micronised material had been 
observed [391. This change affects the surface energy of the particles 
and consequently their interfacial interactions may be responsible for 
the batch variation behaviour of nedocromil sodium. 
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These subtle changes of the surface of the particle have been 
detected by the recently developed techniques of microcalorimetry [41, 
42] and water sorption [431. Unfortunately these techniques were not 
available to me at the time of doing this study. 
12.13 Conclusion 
A series of characterisation techniques have not unveiled a 
detectable difference in the behaviour of five batches of nedocromil 
sodium. More sensitive techniques may have to be employed in order to 
ascertain the reasons that cause variable batch behaviour when the 
drug is presented as an inhalation dosage form. 
The characterisation confirms the batches of materials as 
nedocromil sodium trihydrate, sodium cromoglycate with a typical 






of binary powder mixes 




The aim of this chapter was to prepare binary interactive powder 
mixes and evaluate their structure. The materials characterised in 
Chapter Two were used to prepare the powder blends. The structure of 
the blends was investigated using scanning electron microscopy. 
3.2 Introduction 
Mixing may be defined as a process where two or more 
components are treated so as to he as nearly as possible in contact with 
a particle of each of the other components [441. Two distinct structures 
of powder mixes have been classified. These are non-interactive mixes, 
in which the constituent particles are independent of each other, and 
interactive mixes in which a degree of association takes place between 
the constituents. 
Non-interactive mixing 
Analysis of a non-interacting powder system provides the 
contrast for the interactive type powder mixes. Two species of equally 
sized and weighted non-interacting particles combine to form a mix of 
this type. The distribution of the particles prior to mixing can be 
represented diagrammatically by Figure 3.2.1. The solid and open 
circles represent the two powder species. Before the mixing process is 


















If a perfect mix were formed, both species of powder would have 
the same distribution throughout the mix, each particle being adjacent 
to a particle of the different species for a 50: 50 mix of each component. 
















Mixing is a disorder- creating process and is very unlikely to 
produce the regularity seen in the system of a perfect mix. The best 
attainable mix is the result of a mixing mechanism in which there is 
equal chance of any individual particle being at any given point at any 
one time. The diagrammatic representation of this random mix is 



















The probability of locating a given particle at a given point in a 
non-interactive powder mix containing similar quantities of each 
species can be described by a binomial distribution. From this the 
quality of the random mix can be determined by calculating the 
variance or standard deviation of the drug content of samples taken 
from the mix. Theoretical variances relating to totally unmixed 
(Figure 3.1, equation 3.1) and the random type of mix (Figure 3.3, 
equation 3.2) were developed by Lacey [ 45 1. 
2 
Oro = X. y (equation 3.2.1) 
2 
OrR ýx' 
Yn (equation 3.2.2) 
where x and y are the proportions of the two component powders, n is 
the number of particles and or. and aR are the theoretical variances for 
the unmixed and random systems respectively. 
From this basic principle many formulae have been derived to 
describe real situations where components differ in physical 
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characteristics, and sampling is carried out by different means [46,471. 
These theoretical calculations aim to define the lowest value for the 
standard deviation of samples taken from the mix when the best 
attainable mix has been formed. 
Segregation 
The process of mixing is in dynamic equilibrium with the 
demixing process, segregation [481. Segregation describes the 
preference of particles, possessing a similar property, for being at some 
part of the system [491. Segregation of a powder is caused by 
differences in the physical and mechanical properties of the constituent 
particles. The properties of powders which are known to cause 
segregation include relative density, shape or roughness, resilience and 
relative size of the particles [46). Of all the causes of segregation, 
particle size is considered to be the most important [501. 
Mechanisms of segregation can be considered according to the 
forces acting on the particles. Trajectory segregation occurs when 
particles of different mass are set in motion. Larger particles with larger 
kinetic energies tend to have increased stopping distances. Therefore 
similar particles, having similar stopping distances tend to travel to the 
same areas in the powder bed. Percolation segregation describes the 
mechanism of particles travelling through the voids in the powder bed. 
This can occur either when the powder bed is at rest, or when slip 
planes are formed. DensifIcation segregation occurs when powders of a 
dissimilar size are vibrated. The smaller particles tend to fall through 
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the interstices between the large particles and travel to the bottom of 
the powder bed. 
According to the mechanisms above, mixing a micronised powder 
with larger solid particles would create a mix in which segregation 
would dominate due to the size differences of the powder components. 
A very poor homogeneity would be expected from such a mix. However 
it was first observed by Travers and White [5 11 that these type of mixes 
exhibited a resistance to segregation. 
Interactive mixes 
According to Jones and Pilpel [521 particles below 50, um in 
diameter tend to be adsorbed onto the surfaces of coarser particles in a 
powder mix to form a coating which may or may not be continuous. 
The prevention of segregation by the adsorption of fine particles onto 
larger crystals was identified by Travers and White [511. Hersey [531 
introduced the term of 'ordered mixing' implying the presence of 
adhesion due to particulate interactions. Unfortunately the term 
ordered mixing was used subsequently in the literature with different 
meanings, leading to misunderstanding and ambiguity. 
The term 'order' was originally proposed to distinguish the type of 
mixture and describe its structure [541. Mixes of interactive powders in 
which adhesion takes place between constituents, and mixes of free 




The term 'ordered mix' has been misinterpreted, and has been 
used to describe the degree of homogeneity within the powder blend. An 
incomplete mix, where the standard deviation of drug content in the 
samples is greater than the theoretical best attainable mix according to 
random theory, has been contrasted with an 'ordered mix' in which the 
standard deviation is smaller than expected. 
This confusing terminology was addressed with the suggestion to 
use two terms, one to define the type of mix, and a second to describe 
the level of homogeneity [54,551. The terms interactive and non- 
interactive have now become more acceptable to describe the types of 
mix in which the constituents are cohesive or free flowing respectively 
[56,571. Description of the degree of mixing relates the real mix to the 
best attainable mix according to random theory. The terminology 
incomplete, random and ordered has been suggested to differentiate 
between mixes in which the level of homogeneity corresponds to worse 
than, equal to, and better than that of the theoretical best attainable 
mix [551. However, as much confusion has surrounded the term 
'ordered', it has been suggested that it is preferential to describe the 
level of homogeneity by use of a measure such as standard deviation, 
or simply by a descriptive phrase [541. 
Adhesion mechanisms 
The mechanisms which cause adhesion between solid particles 
are listed below: 
A) Van der Waals' forces 
B) Electrostatic forces 
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Q Forces due to liquid bridges 
D) Mechanical forces, resulting from interlocking of irregularly 
shaped particles 
E) Solid bridging forces, present when individual particles have been 
joined at points of contact by sintering or precipitated impurities. 
F) Magnetic forces, associated with materials having an appreciable 
magnetic moment [581. 
Applied to the situation of dry, solid particles, it is the van der 
Waals' forces which play the most important part in the adhesion 
mechanism [591. 
Van der Waals' forces are short range intermolecular forces, 
which are noticeable only when particles come sufficiently close 
together, that is, separation distances of the order 0.2 nm to I nm. All 
intermolecular forces are essentially electrostatic in origin. The three 
types of force which contribute to the total van der Waals' force are 
orientation (Keesom forces), induction (Debye forces) and dispersion 
(London forces) [601. 
Orientation forces are due to atoms or molecules with permanent 
dipoles. A permanent dipole moment can also polarise a non-polar 
medium, the resultant force being the induction force. Whilst the time 
average variation of charge is zero, the charges and dipoles generated 
by the movement of the charges is subject to statistical variation, the 
same as any other physical variable. These interacting dipoles cause a 
steady, fluctuating electromagnetic field, which results in the 
omnipresent dispersion forces [6 11. 
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The magnitude of van der Waals' forces is proportional to the 
particle diameter. The gravitational force is proportional to the cube Of 
the diameter. Therefore, when the particle diameter exceeds a few 
microns, the magnitude of the van der Waals' force becomes negligible 
when compared with that of the gravitational force. 
The electrostatic attraction between particles can occur to a 
greater extent if the powders are subjected to triboelectrification. The 
relative difference in energy levels of the Fermi electrons can allow 
excipient and drug particles to have different surface charge signs 
which causes interparticulate attraction. The electrostatic charge is lost 
through earth leakage relatively quickly. However, improved van der 
Waals' bonding can take place due to the close surface contacts 
facilitated by the triboelectrification [621. 
Mechanical interlocking creates multiple interparticle contacts 
which increases the magnitude of the van der Waals' forces experienced 
by the particle. It also prevents removal of the adhered particle due to 
abrasion, as the adhered particle experiences a degree of protection. 
This can be seen in Figure 3.2.4. 
Figure 3.2.4 Mechanical interlocking of a small adhered particle [621 Yi 
F2 represent the adhesion forces. 
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Structure of interactive mixes 
It has been stated that ideally the weight of particles of drug 
bound to the carrier particle is in direct proportion to the surface area 
of the carrier particle [631, implying that the carrier particles are 
covered with a monolayer of fine particles [641. The number of fine 
particles which can be accommodated on the surface of each carrier 
particle, assuming a hexagonal close packed arrangement of the fine 




(equation 3.2.3) AA2r2. ý3 
where n number of fine particles 
R, r large particle and small particle radius 
fraction of the maximum number of small 
particles associated with the carrier particle 
If 0 is taken as unity, then the calculation relates to a saturated 
monolayer of fine particles covering the surface of the carrier particle. 
Only one piece of published experimental work has found good 
agreement between the theoretical number of fines associated with 
each carrier particle and the number determined experimentally ( 65 1. 
According to Hersey [531, using a lower concentration of fine 
particles than the saturation value would lead to the total number of 
sites for adhesion not being filled. Conversely, more fine particles than 
the saturation number would lead to the excess fines not adhering and 
behaving as non-interacting particles dispersed in the mix in a random 
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manner. Experimental evaluation has led to the determination of non- 
adhered fine particles in the powder mix [661. 
When the concentration of fine particles surpasses the number 
required to form a monolayer, carrier particles have been observed to 
become spherical or elliptical in shape. It has been suggested that this 
formation of a multi-layer coverage follows a monolayer coverage. As 
the concentration of fines in the mix increases, the multilayer, initially 
filling the void space or surface indentations continues to produce a 
smooth particle [641, as described in Figure 3.2.5. 
Figure 3.2.5 Schematic representation of multi-layer formation [641 
In order to adhere single cohesive partio-cles the mixing process 
must first break down aggregates of the fine powder. This two step 
mechanism for the production of an interactive mix has been suggested 
by Stephenson and Thiel [671 and can be represented diagrammatically 
as shown in Figure 3.2.6. 
Chapter Three 
Adherent particle 
Agglomerate of adherent particles 
Carrier particle 
Figure 3.2.6 Formation of an interactive unit 
The rate of breakdown of these aggregates and formation of a 
homogeneous mix has been shown to be dependent upon the energy 
input from the mixer. [67-691. However it has been shown 
experimentally that the break-up of these cohesive agglomerates is not 
a rate limiting step at the early stage of mixing [701. 
It has been suggested that the agglomerates formed due to the 
cohesive nature of the fine particles could randomly mix with the 
coarse particles, in a non-interactive manner [711. A combination of 
interactive and non-interactive behaviour has also been suggested, 
whereby a uniformed weight fraction leaves the agglomerates and 
adheres uniformly to the carrier particles [721. Each adhesive 
interaction which has been considered involves a single fine particle 
adhering to a carrier particle as part of the process to form a monolayer 




As with non-interactive powder mixes, the degree of mixing can 
be expressed by the comparison of the sample standard deviation of 
drug content of the withdrawn samples and the sample deviation for a 
random mixture, crR , of the same system. 
With the introduction of the concept of fine particle adhesion in 
interactive mixes came the suggestion that the homoLseneitv of such 
powder mixes would be of a higher degree than that observed in the 
best attainable non-interacting random mix [531. This has been 
supported by experimental findings [67,68,731. 
Increased homogeneity in interactive mixes has since been 
established as an ideal situation, and is unlikely to occur in real 
powder mixes [541. Statistical and experimental analysis have shown 
that the best degree of homogeneity seen in interactive mixes 
corresponds to that of a fully randomised system [65,74,751. This is 
due to non-uniform distribution of fine particles on the carrier, a range 
of carrier and fine particle sizes, and unsatisfactory calculation of the 
sample variance of a random mix for the same system. 
In order for homogeneity to increase, complete adhesion of an 
identical number of equally sized fine particles to each coarse, 
monosized carrier particle must take place [ 75 1. 
Microscopic examination of interactive mixes has shown that the 
drug particles have a tendency to adhere to surface irregularities of the 
carrier particle [761. This verifies the suggestion that indentations of 
Page 96 
Chapter Three 
the carrier's surface are initially the sites of adherence for the fine 
particles [51,66,771. This has led to the implication that the physical 
properties of the carrier particle surfaces are more important than pure 
stereometry [ 76 1. 
Sites for adhesion due to surface indentations trapping particles, 
electrostatic forces [621, van der Waals' forces [641 and moisture 
bonding [781 have been suggested. 
Individual carrier particles are not equivalent with respect to 
their relevant surface properties, and therefore to their binding capacity 
[751. This erratic distribution of fine particles on the surface of the 
carrier has been observed experimentally [79,801. 
Therefore, because no mechanism exists to control the 
distribution of the adhering small particles, the state of random 
adhesion has been suggested [75]. This implies a random distribution 
of fine particles on the carrier surface. If the adherence occurs in a 
random fashion, then the quality of a fully randomised system can be 
achieved at best. 
The Stange-Poole equation [811, a derivation from Lacey's 
binomial approach, was used to calculate the sample variance for the 
random mixture when a greater degree of homogeneity for the 
interactive mixes was claimed [67,68,731. Theoretically, the variance 
of a random mix for a system containing a minor drug component, as is 
often the case in pharmaceutical powders, should be derived from the 
Poisson distribution [821. Achieving a lower sample variation 
experimentally than that estimated for a random mix cannot, 
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therefore, imply a greater degree of homogeneity as the equation used 
to estimate the random quality did not apply to the system examined 
[831. 
For pharmaceutical preparations, it is not the absolute standard 
deviation but the coefficient of variation which is of interest. This 
follows from the tolerance limits for the drug content variation of dose 
units being stated as a percentage of the mean drug content. The 
percentage coefficient of variation is the standard deviation (a) 
expressed as a percentage of the arithmetic mean (y): 
C. v= (Or/ft) x 100 (equation 3.2.4) 
Since a and y are both expressed in the same units as the variate, 
C. V. is independent of the units of measurement [841. 
As stated earlier, the theoretical best possible mix of interactive 
constituents is one in which the fine particles are adhered in a random 
manner. The homogeneity of such a mix can be estimated from the 
Poisson distribution. Equation 3.2.5 derived by Johnson [851 and 





where CR is the coefficient of variation of drug content as a percentage 
of the mean content G of the adherent ingredient per sample, and m- is 
the volume-weighted mean particle mass of the ingredient. This 
assumes a mono-disperse diluent. 
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Identification of an interactive mix 
It has been suggested in the literature that the creation of an 
interactive powder mix could be identified by the relationship between 
the sample variance and the sample size. When dealing with non- 
interacting powder mixes the relationship between the sample size and 
the sample deviation is such that the variance of the sample decays 
inversely with the sample size [45,871. Formation of an interactive 
powder mix has been suggested to lead to a constant standard 
deviation (a) of the samples which is independent of the sample size 
[681. This relates to the ideal interactive mix where complete adhesion 
of an identical number of equally sized fine particles to each coarse, 
monosized carrier particle takes place, and or= 0 is purely theoretical 
[541. The experimental data to support this suggestion [67,68,731 has 
been questioned by Orr [881, who suggested the real relationship 
between sample variance and size was being masked by large standard 
errors due to sampling and analytical procedures. A computer 
simulation of ordered mixes [891 showed that there was an inverse 
relationship between the sample standard deviation and the square 
root of the sample size for both interacting mixes and non-interacting 
random mixes. 
Segregation 
The interest in interactive mixes developed from the phenomena 
that this type of mix showed a unexpected resistance to segregation 
[5 11. However this does not imply that segregation does not take place - 
Drug-lean and drug-rich areas have been determined in interactive 
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mixes [501. These can be explained with the concepts of 'constituent' 
and ordered unit' segregation [901. 
Constituent segregation results from the disassociation of the 
adhered fine particle and the larger carrier particle. This occurs if the 
force applied to the mixture is sufficient to break the adhering bond 
between the particles [901. After the breakdown of the interactive units 
the two ingredients have to separate and travel to distinct parts of the 
powder bed [501. The mechanism for this is identical to percolation 
segregation as observed in non-interacting mixes [911. 
The term 'ordered unit' has been used to describe a single carrier 
particle with its associated small particles adhered to the surface. The 
segregation of these ordered units can occur due to differences in 
carrier particle size and/or density. Assuming an ideal interactive mix, 
where a complete monolayer of fine particles covers the surface of the 
larger particle, segregation of particle size of the vehicle will lead to rich 
and poor fractions of the drug. Fractions containing large particles of 
vehicle will have a low surface area and hence be poor in drug content. 
The converse will also be true [901. 
The stability of interactive mixes has been studied experimentally 
[50,76,90,92,93]. Although the ideal interactive mix is not achieved 
when mixing real powders examples of both 'constituent' and 'ordered 
unit' segregation were observed. 
The structure of an interactive powder mix, therefore is a 
reflection of any adhesive and cohesive interactions which are taking 
place. These interactions, whilst improving flow characteristics of 
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powder doses, and providing a means of delivering very small doses of 
potent actives, may influence the delivery of drug from the powder 
blend. Therefore, the determination of the structure of binary powder 
blends used for inhalation therapy will elucidate the extent of adhesive 
and cohesive interactions. The investigation of the effect of drug 
concentration and drug type may lead to different drug release 




a 3.3 Experimental 
Two component, drug and carrier, powder mixes were prepared. 
The drug species investigated were nedocromil sodium, sodium 
cromoglycate and reproterol. The carrier species was a -lactose 
monohydrate. The mixes were assessed for their homogeneity. Image 
analysis and scanning electron microscopy were carried out in order to 
observe the structure of the mixes. 
3.4 Materials 
The following drug and lactose samples were used to prepare the binary 
nuxes. 
Sample Batch 
Nedocromil sodium 5B I 
Sodium cromoglycate XC 13 CIA M 150 
Reproterol. 092125 M153 
a lactose monohydrate 022303 and 022301 





3.5.1. a Theory 
The maximum number of fine particles which can be 
accommodated by the surface of a carrier particle can be derived using 






Taking 0 to be unity assumes a saturated monolayer. The drug 
concentrations which correspond to a monolayer coverage of every 
carrier particle in the mix, calculated using equation 3.5.1 are shown in 
Table 3.5.1. 
Drug Number of drug Ma2dmum drug 
particles per carrier concentration 
particle (%w/w) for 
monolayer formation 
Nedocromil sodium 384 7.15 
Sodium cromoglycate 373 7.32 
Reproterol 816 4.40 
Table 3.5.1 Drug concentrations for binary interactive mixes 
The coefficient of variation for the mixes of nedocromil sodium, 
sodium cromoglycate and reproterol calculated using equation 3.25 




Mean volume diameter (Coulter Counter Analysis) = 2.677, um 
True particle density = 1.583 g/ cm 3 
Mean particle mass of drug particles = 1.583 x 10 g 
% w/w drug content 
in mix 
Mean content of 
drug per 25 mg 




0.4 1.0 X 10 -4 4.0 x 
10-2 
1.0 2.5 X 10-4 2.5 X 10-2 
2.0 5.0 X 10-4 2.0 X 10 -2 
4.0 1.0 X 10-3 1.3 x 
10-2 
40.0 1.0 X 10-2 4.0 X 10-3 
Table 3.5.2 Calculated values for nedocromil sodium powder mixes 
Sodium cromoglycate 
Mean volume diameter (Coulter Counter Analysis) = 2.078, um 
True particle density = 1.590 gl CM3 
Mean particle mass of drug particles = 7.470 X 10-12 g 
% w/w drug content 
in mix 
Mean content of 
drug per 25 mg 






1.0 X 10-4 2.7 X 10-2 
1.0 2.5 X 10-4 1.7 X 10-2 
2.0 5.0 X 10-4 1.2 X 10-2 
4.0 1.0 X 10-3 8.6 X 
10-3 
40.0 1.0 X 10-2 2.7 X 10-3 




Mean volume diameter (Coulter Counter Analysis) = 2.041 Ym 
True particle density = 1.445 g/ CM3 
Mean particle mass of drug particles = 6.432 X 
10-12 9 
% w/w drug content Mean content of Calculated 
in mix drug per 25 mg coefficient of 
sample (g) ('G'eqn 3.2.5) variation (%) 
o. 15 3.8 x 10-5 4.1 X 10-2 
1.5 3.8 X 10-4 1.3 X 10-2 
4.0 1.0 X 10-3 8.0 X 10-3 
Table 3.5.4 Calculated values for reproterol powder mixes 
These values represent the theoretical best attainable mix for the 
systems in question and therefore the smallest possible values for the 
coefficient of variation. 
A poor quality mix will be reflected by a large value for the 
coefficient of variation. Experimental determination has led to an 
acceptable coefficient of variation of less than 2.5 %. Values greater 




3.5. l. b Method 
Drug and lactose samples were weighed using a Mettler AT261 
balance. The quantity of each powder mix allowed a 50 % void space 
within the mixing container. 
A specially constructed stainless steel mixing cylinder was used 
to prepare the mixes. Curved internal joints replacing the 90' angles 
reduced the dead space in the vessel. The capacity of the vessel was 
160 CM3. 
The weighed samples were transferred to the mixing vessel and 
were mixed for 5 minutes using a Turbula mixer ( T2C, W. A. Bachofen, 
Switzerland) set at 90 revolutions per minute (corresponding to 1.5 Hz). 
The vessel was then removed from the mixer and gently tapped in order 
to dislodge any mix which had become adhered to the vertices of the 
vessel. This was followed by another 5 minute mixing time at the same 
settings. 
Mixes were initially produced with no preparation of the sample. 
Subsequent mixes used drug powder which had been screened through 
a 63, um sieve. 
3.5.2 Homogeneity testing 
The quality of the mixes was assessed by evaluating the 
homogeneity. Samples of the dose size, 25 mg, were taken from the 
mix. The samples were dissolved in deionised water and immediately 
assayed for drug content by UN spectroscopy. The percentage 
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coefficient of variation for the ten samples was acceptable at a value 
below 2.5%. 
3.5.3 Image analysis and scanning electron microscopy 
Image analysis and scanning electron microscopy were employed 
in order to identify the structure of the interactive mixes. Image 
analysis was carried out using a Zeiss A)doskop microscope, images 
being produced using a Mitsubishi colour video copy processor (CP 
100B). International Scientific Instruments DS130 and a Jeol JSM35 
scanning electron microscopes were both used to produce 
photomicrographs of the powder mixes. Particles were sputtered with 





3.6.1 Homogeneity testing 
3.6.1 a Nedocromil sodium 
Binary mixes of nedocromil sodium with lactose at a 
concentration of 0.4% w/w hydrated drug were prepared from drug 
samples which had been previously either unscreened or screened 
through a 63, um sieve. The assay results of the samples taken ftom the 
mixes are shown in Figure 3.6.1. 












12345678 910 123456789 10 
Sample number 
Not prescreened drug Prescreened drug 
Figure 3.6.1 Assay results for 0.4 %w/w drug mix of nedocromil 
sodium with lactose 




Sample Mean drug content Drug content coefficient 
preparation per sample (mg) of variation (%) 
Not pre-screened 0.129 54.399 
Pre-screened 0.098 0.985 
Table 3.6.1 Comparison of the effect of nedocromil sodium sample 
preparation upon the powder mix homogeneity 
All of the binary mixes subsequently prepared used nedocromil 
sodium which had been screened through a 63, um sieve. 
The following powder blends were prepared. The corresponding 
percentage coefficient of variation for ten dose weight samples taken 
from each batch is shown in Table 3.6.2. 





% w/w drug content 
by assay 
0.4 0.985 0.392 
1.0 0.854 0.985 
2.0 0.450 1.956 
4.0 0.750 3.908 
40.0 7.371 37.629 
Table 3.6.2 Nedocromil sodium powder mix homogeneity data 
Page 109 
Chapter Three 
3.6.1b Sodium cromoglycate 
Binary mixes of sodium cromoglycate with lactose at a 
concentration of 0.4% w/w hydrated drug were prepared from drug 
samples which had been previously either unscreened or screened 
through a 63, um sieve. The assay results of the samples taken from the 
mixes are shown in Figure 3.6.2. 







123456789 10 12345678 910 
Sample number 
Not prescreened drug Prescreened drug 
Figure 3.6.2 Assay results for 0.4 %w/w drug mix of sodium 
cromoglycate with lactose 




Sample Mean drug content Drug content coefiricient 
preparation per sample (mg) of variation 
Not pre-screened 0.104 23.591 
Pre-screened 0.099 1.444 
Table 3.6.3 Comparison of the effect of sodium cromoglycate sample 
preparation upon the powder mix homogeneity 
All of the binary mixes subsequently prepared used sodium 
cromoglycate which had been screened through a 63, um sieve. 
The following powder blends were prepared. The corresponding 
percentage coefficient of variation for ten dose weight samples taken 
from each batch is shown in Table 3.6.4. 





% w/w drug content 
by assay 
0.4 1.444 0.394 
1.0 0.937 0.960 
2.0 2.318 1.905 
4.0 1.684 3.704 
40.0 2.130 39-156 
Table 3.6.4 Sodium cromoglycate powder mix homogeneity data 
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3.6.1 c Reproterol 
Binary mixes of reproterol with lactose at a concentration of 
0.15% w/w drug were prepared using drug samples from drug samples 
which had been previously. either unscreened or screened through a 
63 ym sieve. The assay results of the samples taken from the mixes are 
show, n in Figure 3.6.3. 
0.15% w/w reproterol with lactose 
0.20 
123456789 10 12345678 910 
Sample number 
Not prescreened drug Prescreened drug 
Figure 3.6.3 Assay results for 0.15 %w/w mix of reproterol with lactose 
The mean and coefficient of variation for both mixes are shown in 
Table 3.6.5. 
Sample Mean drug content Drug content coefficient 
preparation per sample of variation 
Not pre-screened 0.056 75.297 
Pre-screened 0.038 1.454 
Table 3.6.5 Comparison of the effect of reproterol sample preparation 
upon the powder mix homogeneity 
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All of the binary mixes subsequently prepared used reproterol 
which had been screened through a 63, um sieve. 
The following powder blends were prepared. The corresponding 
percentage coefficient of variation for ten dose weight samples taken 
ftom each batch is shown in Table 3.6.6. 
% w/w hydrated Drug content % w/w drug content 
drug content coeWicient of by assay 
variation 
0.15 1.454 0.150 
1.50 1.179 1.475 
4.0 9.062 4.034 
Table 3.6.6 Reproterol mix homogeneity data 
3.6.2 Discussion 
All of the powder mixes exhibit a very poor homogeneity when the 
drug sample was not sieved prior to mixing. This is due to incomplete 
deaggregation of drug clusters which form in the bulk powder upon 
storage. The samples taken for homogeneity analysis which are very 
rich in drug content suggests that drug aggregates are present. These 
are in contrast with the very drug lean samples which suggest that very 
little drug has become adhered onto the carrier particles. Therefore 
interactive units have not been formed, 
Preparing the drug by sieving immediately before mixing breaks 
down the clusters of drug which form during storage. The short range 
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van der Waalss bonds are disrupted and the structure of the aggregate 
breaks down. The very small sample coefficient of variation suggests 
that the process of pre-sieving encourages the formation of interactive 
units. Had interactive units not been created the expected constituent 
segregation would lead to a very poor homogeneity reflected by a high 
sample standard deviation and corresponding coefficient of variation. 
The percentage coefficient of variation achieved for the mixes 
containing 40 % w/w nedocromil sodium and 4% w/w reproterol he 
outside the acceptable limit for interactive mix formation. 
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3.6.3 Visual analysis of the powder blends 
Microscopic image analysis and scanning electron microscopy 
and were used to produce visual images of the powder mixes. 
Photomicrographs produced from image analysis of the series of 
powder mixes increasing in drug concentration show the progressive 
change in structure of the mix with an increasing drug load. 
Figure number Drug species Drug concentration 
3.6.4 nedocromil sodium 0.4 % w/w 
3.6.5 nedocromil sodium 1.0 % W/W 
3.6.6 nedocromil sodium 2.0 % w/w 
3.6.7 nedocromil sodium 4.0 % w/w 
3.6.8 nedocromil sodium 40 % w/w 
3.6.9 sodium cromoglycate 0.4 % w/w 
3.6.10 sodium cromoglycate 1.0 % W/W 
3.6.11 sodium cromoglycate 2.0 % w/w 
3.6.12 sodium cromoglycate 4.0 % w/w 
3.6.13 sodium cromoglycate 40 % w/w 
3.6.14 reproterol 0.15 % w/w 
3.6.15 reproterol 1.5% w/w 
3.6.16 reproterol 4.0 % w/w 
Table 3.6.7 Scanning electron micrograph summary 
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Figure 3.6.4. Nedocromil sodium/lactose powder mix 0.4 % w/w drug 
concentration. Magnification x 160. 
Figure 3.6.5. Nedocromil sodium/lactose powder mix 1.0 % w/w drug 
concentration. Magnification x 1.60 - 
Chapter Three 
Figure 3.6.6. Nedocromil sodium/lactose powder mix 2.0 % w/w drug 
concentration. Magnification x 160. 
Figure 3.6.7. Nedocromil sodium/lactose powder mix 4.0 % w/w drug 
concentration. Magnification x 160. 
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Figure 3.6.8. Nedocromil sodium/lactose powder mix 40 % w/w drug 
concentration. Magnification x 160. 
Figure 3.6.9. Sodium cromoglycate /lactose powder mix 0.4 % w/w 
drug concentration. Magnification x 160 
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Figure 3.6.10. Sodium cromoglycate / lactose powder mix 1.0 % w/ w 
drug concentration. Magnification x 160. 
4 
Figure 3.6.11. Sodium cromoglycate /lactose powder mix 2.0 % w/w 
drug concentration. Magnification x 160 - 
Page 119 
Chapter Three 
Figure 3.6.12. Sodium cromoglycate /lactose powder mix 4.0 % w/w 
drug concentration. Magnification x 160. 
Figure 3.6.13. Sodium cromoglycate /lactose powder mix 40 % w/w 
drug concentration. Magnification x 160 - 
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Figure 3.6.14. Reproterol /lactose powder mix 0.15 % w/w drug 
concentration. Magnification x 160. 
Figure 3.6.15. Reproterol/ lactose powder mix 1.5 % w/w drug 
concentration. Magnification x 160. 
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Figure 3.6.16. Reproterol/ lactose powder mix 4.0 % w/w drug 
concentration. Magnification x 160. 
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3.7 Discussion 
The powder mixes, up to and including the 4 %w/w drug 
concentration, contain sufficient carrier surface to accommodate the 
drug particles in a monolayer arrangement as described by equation 
3.5.1. However, from the micrographs it can be seen that a monolayer 
arrangement is not favoured. Small drug aggregates are adhered to the 
surface of the lactose particle. These surface-held aggregates are 
observed at all concentrations of each species of drug mix. 
This confirms that the adhesion of ftne particles occurs in a non - 
uniformed manner, as suggested by Ergermann [751. The adhesion of 
small aggregates rather than isolated particles accounts for the large 
deviation of coefficient of variation (%) of samples taken from the 
powder mixes from that expected according to equation 3.5.1. Although 
the structure of the mixes indicates adhesive interactions take place, 
these do not occur at the expense of the cohesive interactions. This 
suggests that the formation of a carrier particle with a monolayer 
coating of drug is not the most energetically favourable situation. 
Within each series of powder mixes the number of adhering 
aggregates increases with the drug load up to 4% w/w. These 
aggregates appear to be a similar size for each drug species throughout 
the series. 
This suggests that an energy limiting factor may determine a 
critical size of adhering aggregate. The abrasion which occurs during 
the mixing process may remove large surface held drug aggregates. 
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These observations suggest that the formation and size of the adhered 
aggregates is not drug dependent 
Further analysis using scanning electron microscopy provides 
more information about the structure of the drug/carrier interactive 
units. The surface held aggregates can be identified in all of the 
drug 
mixes at 4 %w/w concentration, as shown in Figures 3.7.1,3.7.2 and 
3.7.3. 
Figure 3.7.1 Scanning electron micrograph of nedocromil 
sodium/lactose powder mix 4.0 %w/w drug concentration. 
Picture number 1943. 
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Figure 3.7.2 Scanning electron micrograph of sodium 
cromoglycate /lactose powder mix 4.0 %w/w drug concentration. 
Picture number 2029. 
Figure 3.7.3 Scanning electron micrograph of reproterol/ lactose 




Examining these surface-held aggregates at higher magnification 
shows that the cluster of drug particles appear to be attached via a 
small number of adhered particle. These can be seen in figures 3.7.4 
and 3.7.5. These anchor particles may be single adhered drug particles, 
or fines of lactose which had previously been attached to the surface of 
the larger lactose crystals, as seen in Figure 2.2.9. 
Figure 3.7.4 Scanning electron micrograph of sodium 
cromoglycate /lactose powder mix 4.0 %w/w drug concentration. 
Picture number 2039. 
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Figure 3.7.5 Scanning electron micrograph of sodium 
cromoglycate /lactose powder mix 4.0 %w/w drug concentration. 
Picture number 2026. 
Drug aggregates which are not associated with the lactose 
surface can be seen in the mix of nedocromil sodium at 4 %w/w, Figure 
3.7.6. These aggregates were not observed in the mixes of sodium 
cromoglycate and reproterol at the same concentration. 
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Figure 3.7.6 Scanning electron micrograph of nedocromil 
sodium/lactose powder mix 4.0 %w/w drug concentration. 
Picture number 0695. 
At 40 %w/w drug load both the nedocromil sodium and sodium 
cromoglycate mixes contained large non-adhered aggregates. These co- 
exist with the surface held drug aggregates. These can be seen in 
figures 3.7.7 and 3.7.8. The small interacting drug clusters are 
associated with the surface of both the lactose particles and the non- 
interacting aggregates. 
The image analysis micrographs of both mixes show that the 
non-adhered aggregates of nedocromil sodium are about 95, um 
diameter compared with the non-adhered aggregates of sodium 
cromoglycate which are about 55, um diameter. 
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The sample coefficient of variation (%) for these two mixes is 
7.4 % and 2.1 % respectively. Non-adhered aggregates are present in 
both mixes, although only the mix prepared from sieved nedocromil 
sodium and lactose has a high coefficient of variation. The non- 
interacting aggregates formed in the mix of nedocromil sodium 
therefore, tend to segregate from the interactive units producing a mix 
with a poor homogeneity. The non-interacting aggregates formed in the 
sodium cromoglycate mix have a more random distribution producing a 
more homogeneous mix. 
When compared with the non-interacting aggregates observed in 
the 4% w/w drug concentration mix of nedocromil sodium, it appears 
that the drug load influences the aggregate size. Aggregates having a 
diameter < 50, um are observed in the lower drug concentration mix 
(Figure 3.7.6) compared with the larger aggregates seen in the mix 
containing a higher concentration of drug. 
Figure 3.7.7. Nedocromil sodium/lactose powder mix 40 % w/w drug 
concentration. Magnification x63. 
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Figure 3.7.8. Sodium cromoglycate /lactose powder mix 40 % w/w drug 




An interactive powder mix resists segregation due to the adhesive 
interactions which occur between the small particles and the larger 
sized carrier species. A system which provides sufficient carrier surface 
to accommodate all of the small adhering particles has the potential to 
create the ideal monolayer coverage of the carrier by the adhered small 
particles. The tendency for the fine particles to form small aggregates in 
real binary powder mixes rejects the idea that monolayer coverage of 
the carrier particle with the fine particles will occur. 
The structure of binary powder mixes of the drugs used for 
inhalation therapy and lactose deviated from that of an ideal interactive 
powder mix. Within powder systems which had the potential to create 
an ideal interactive mix, drug particles were adhered to the surface of 
the particles of lactose as single units and small drug clusters. The 
mechanism for the formation of these interactive units is unclear. It is 
possible that the small aggregates of drug are created in the mix due to 
the cohesive nature of the drug particles. These aggregates may then 
become adhered to the surface of the lactose particle. Alternatively, the 
surface held aggregates may be formed due to cohesive interactions 
taking place between drug particles which are adhered to the lactose 
and free drug particles. In either case the cohesive interactions of the 
drug particles are favoured rather than adhesive interactions between 
drug and lactose particles. 
The cohesive interactions are responsible for the formation of 
non-interacting aggregates of drug. These are formed in the binary 
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mixes in which the drug load exceeds the surface available for adhesion 
provided by the lactose particles. The formation of these larger 
aggregates does not occur at the expense of the surface held small drug 
aggregates, as both types of drug cluster co-exist within the powder 
mixes. Drug load is a contributing factor to the formation of these non - 
adhering drug aggregates. However, their formation is not limited to 
systems which have a drug concentration greater than that required to 
cover lactose particles with a monolayer. 
Competition exists, therefore, within the powder mixes between 
the cohesive interactions which are responsible for aggregate formation, 
and the adhesive interactions which are responsible for the formation 
of interactive units. 
The structure of the mixes of the powder systems under 
investigation suggest that the equilibrium point between the adhesive 
and cohesive interactions is drug specific. Identical systems which 
differed only in type of drug varied in structure with respect to the drug 
load at which non-adhering aggregates were formed, the size of the 
non-adhering aggregates and the coverage of the lactose particles by 
surface held aggregates. The results suggests that the cohesive 
interactions are more dominant for mixes containing nedocromil 
sodium than they are for the corresponding mixes containing sodium 
cromoglycate and mixes of reproterol as the drug type. 
As determined in Chapter Two, the size, shape and density of 
particles of nedocromil sodium, sodium cromoglycate and reproterol are 
similar. This suggests that these samples of drug would tend to behave 
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in a similar manner in a binary powder mix. As discussed in Section 
2.12, very small differences in surface characteristics can be very 
influential upon surface energies of particles. Therefore, although 
similar in physical characteristics, it is possible that differences in 
surface characteristics between drug types have led to different 
interactive behaviour. It was not possible to identify these differences 
with the techniques used in this chapter. 
The effect of the structure of these interactive mixes upon the 
performance of the dose as a dry powder inhalation were investigated in 
Chapter Four. 
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performance of binary 




The structure of the binary Interactive mixes prepared for drug 
pulmonary delivery from a dry I powder inhaler were evaluated in the 
previous chapter. The aim of this present chapter was to determine the 
performance of the powder mixes in their ability to deliver the dose of 
drug to the lungs, leading to the elucidation of a relationship between 
blend structure and performance. 
4.2 Introduction 
As described in Chapter One, the dimensions of drug particles 
must lie within a narrow size range for efficient pulmonary delivery and 
deposition. Deviation from these limits (2 jim to 5, um) leads to 
deposition in the upper respiratory tract (if too large) or exhalation (if 
too small). 
The inhalation system must therefore produce an aerosol cloud in 
which the drug particles e3dst as single entities. To do this, two distinct 
processes must take place. The first is the transfer of the powder from a 
static powder bed into an airstream. The second phase is the break-up 
and dispersion of the aggregates in the aerosol cloud into individual 
particles. The performance of the inhalation system is a measure of how 
efficiently the drug is fluidised and then dispersed into primary drug 
particles. 
Several in vitro methods have been developed to mimic the 
deposition of an aerosol in the lungs. As discussed previously, 
(section 1.1), the depth of penetration into the lungs is dependent upon 
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the particle size. As the particle size decreases the particles can 
penetrate and are deposited further into the bronchial tree towards the 
alveoli. Experimental methods are based upon inertial impaction which 
dynamically separates the aerosol cloud into size fractions. 
4.2.1 Inertial separation apparatus 
Test equipment used to classify an aerosol cloud by inertial 
separation are based upon the 'cascade impactor' developed by May 




Trajectory of particle too 
/small to impact 
w 
Impaction surface 
Figure 4.2.1 Process of inertial impaction 
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At each stage of the apparatus the airstream is presented with an 
0 obstacle such as a plate and has to deflect through 90 . The 
combination of the standard volumetric flow rate and the jet width 
determines the velocity of the air at the point of deflection. Particles 
with sufficient inertia (resistance to change in velocity) are unable to 
adapt to the change in direction at this point and become impacted 
onto the plate. Those particles which do not have sufficient inertia 
remain in the airstream and travel through the stage, further into the 
apparatus. 
Each stage has progressively finer jets. Therefore the velocity of 
the air at the point of deflection is progressively greater. At each stage 
the largest remaining particles are removed due to their inertia and are 
deposited on the plate. Therefore the aerosol cloud is separated into 








%% "1 11 
Jet 3 
Firsure 4.2.2 Sectional elevation of cascade impactor [951 (not to scale) 00 
The cascade impactor designed by May has been the basis for the 
development of many instruments used to evaluate inhaler 
performance. All are based on the principle of inertial separation and 
can be classified into dry-stage impactors, wet-stage impactors and 
irnpingers. 
4.2.2 Dry-stage impactors 
These instruments vary significantly in design with respect to the 
number of stages, number of orifices at each stage, collection surfaces, 
recovery of the samples and recommended air flow rates. The collection 
surfaces of such apparati have to ensure the impacted particles remain 
associated with the impaction plate whilst the inhalation cycle takes 
place. Different materials can be used to construct the collection plate 
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[96,971 or the surfaces can be coated with a range of materials [6,98, 
991. However, the high jet velocity at the point of deflection still causes 
particles to be blown off the plate and become airborne once again [97, 
98,1001. Liquid aerosol particles are less prone to this overloading 
effect than solid aerosol particles [ 10 1,102). In order to evaluate the 
deposition at each stage the plates are removed from the apparatus and 
either weighed or washed and the solutions assayed for drug. The 
Anderson sampler has been widely used recently in the evaluation of 
metered dose and dry powder inhalation systems [97,103-1071. Other 
dry impactors recently used in aerosol evaluation include the Pilat 
Mark 3 impactor [991, Delron stacked sampler [6,96,97,108], and 
Castella Cascade Impactor [981. 
4.2.3 Wet-stage impactors 
A wet-stage impactor known as a multi-stage liquid impinger 
(MSLI) was developed by May [ 109 1. In order to avoid particle 'bounce 
off, each stage of the apparatus contains a sintered glass disk 
moistened with a suitable liquid. The liquid is placed in each stage until 
the level just reaches the lower surface of this collection plate. The 
upper surface of the plate is kept moist by capillary action. Three upper 
stages each have a single jet and impaction plate. The final fourth stage 
of this apparatus consists of a liquid swirl impinger. This stage has no 
compaction plate, but the nozzle is directed tangential to the wall, such 
that the particles impinge into the liquid. It has been suggested that 
this type of instrument is more appropriate for analysis of concentrated 
powder aerosols than dry-stage impactors [I 101. The multi-stage liquid 




Instead of plates onto which particles impact, stages of impingers 
contain a quantity of liquid into which the particles impinge. The 
airstream is deflected and the cloud loses the large particles which do 
not adjust to the change in direction. Instead of becoming impacted 
onto collection plates, the particles are dissolved or suspended in the 
liquid. The two-stage impinger was developed as an instrument to 
quickly assess the performance of an inhalation device [1141. The 
second stage of the apparatus collects the fraction of the aerosol cloud 
which would penetrate into the lungs, known as the respirable fraction. 
This apparatus was accepted as a method for inhalation evaluation in 
the British Pharmacopoeia 1988 [1151. It has recently been used to 
evaluate both multi-dose pressurised inhalers and dry-powder inhalers 
[116-1181. 
4.2.5 Pre-separators 
Most inertial separation instruments are used in conjunction 
with an induction port. This piece of apparatus is used to remove the 
very large aggregates from the cloud, and represents the deposition 
which would occur in the oro-pharyngeal area. The design of this 
'throat' section has taken the form of either a cylindrical tube with a 900 
bend [ 104,110,1111, or a specially constructed piece of glassware [ 103, 
1191. This pre-separator eliminates some error associated with particle 
bounce from the first impaction stage of the separator as the 
overloading effect of this first stage is decreased. 
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4.2.6 Aerodynamic diameter 
Two particles which are aerodynamically indistinguishable 
because they have similar behaviour in a moving airstream may differ 
in their shape, size and/or density [ 120 1. The aerodynamic property of a 
particle may be described by its aerodynamic diameter. This equivalent 
nieasurement corresponds to the diameter of a sphere of unit density 
which assumes the same terminal settling velocity as the particle in 
question, regardless of its shape and density. 
Stokes' law determines the terminal settling velocity of a sphere 
in the laminar region, as described by equation 4.1. 













In terms of aerodynamic diameter, the sedimentation velocity can 
be described by equation 4.2 [1211 
ts 
where 
2 (po. Dae . 9)/ 




po ý unit density (1 gl cm 3 
Dae 
-, s aerodynamic diameter 
Stokes' law assumes an object moving in a continuous medium. 
If the particles are very small this picture is no longer applicable as the 
particle can 'slip' through the medium. In these cases, for particles 
smaller than I um a slip correction factor, CvP must be applied [ 5,9 7, 
1141. 
For spherical particles which are sufficiently large compared to 
the mean free path in the gas Dae can simply be related to the diameter 
of the sphere and its density [971, as shown in equation 4.3. 
Dae 
W ý. D ýV/Po) 
where D= particle diameter 
(equation 4.2.3) 
The aerodynamic diameter of an airborne particle is the most 
important property in determining its respiratory deposition. The 
impaction surface in inertial separators act as a separator of the 
airborne particles into two sizes; those which are impacted are larger 
than the aerodynamic diameter parameter associated with the 
impaction surface, those which remain airborne are smaller. 
The inertial impactor is therefore a useful tool to evaluate aerosol 
clouds as the parameter measured is that which determines pulmonary 
deposition. 
Data provided by inertial impaction analysis is used to evaluate 
the inhaler device and formulation as a drug delivery system. This can 
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be presented either as particle size distribution within an aerosol (Mass 
Median Aerodynamic Diameter), or as the likely respiratory 
penetrability of an aerosols without determining the absolute particle 
size (Respirable Fraction). 
4.2.7 Mass Median Aerodynamic Diameter 
Each stage of an inertial separator can be described by its 
collection efficiency. This is defined as the percentage of particles of a 
particular aerodynamic diameter which are deposited on the stage. 
Ideally the collection efficiency should increase from 0% to 100 % in a 






Figure 4.2.3 Ideal impaction curve 
Inertial impactors can be calibrated in terms of the range of 
particle sizes collected at each stage at a given flow rate using 
Monodisperse aerosols [ 1231. The aerodynamic diameter for which the 





diameter' and is used as the calibration value. When handling data it is 
assumed that all of the particles with a diameter larger than the 
effective cut off diameter are retained on the stage [961. 
Cascade impactors have been used to estimate particle size and 
distribution within the aerosol cloud. In order to do this the amount of 
drug impacted onto each stage is quantified as a relative percentage of 
the total drug impacted on all of the stages. A cumulative percent value 
can then be determined for each stage. Log-probability plots of 
cumulative percent data versus the aerodynamic diameter of each stage 
can yield values for the Mass Median Aerodynamic Diameter and the 
Geometric Standard Deviation of particles in the cloud. The Mass 
Median Aerodynamic Diameter is obtained by determining the 
aerodynamic diameter which corresponds to 50 %. This is the single 
aerosol measurement which, according to the Task Group on Lung 
Dynamics of the International Commission on Radiological Protection 
[1241, can estimate the regional deposition of particles within the 
respiratory tract. The Geometric Standard Deviation describes the 
degree of polydispersity of the aerosol. Using impactor data, this can be 
calculated by determining the aerodynamic diameter corresponding to 






Where GSD Geometric Standard Deviation 
D84.1% aerodynamic diameter corresponding to 84.1 % 
D15.9% aerodynamic diameter corresponding to 15.9 % 
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4.2.7 Respirable Fraction 
The Glaxo Twin Impinger apparatus does not provide sufficient 
data to permit analysis of a particle size distribution, but it does 
determine the respirable fraction of the aerosol cloud. This corresponds 
to the mass of drug deposited in the second stage of the apparatus. The 
first stage is designed to have an effective cut off diameter of 6.4 Ym. 
The apparatus was designed such that the respirable fraction 
corresponds to particle deposition in stages 3,4 and filter of the multi- 
stage liquid impinger [ 1141. 
4.2.8 Using impingers; to evaluate aerosol clouds from dry 
powder inhalers 
4.2.8. a Method 
The British Pharmacopoeia [ 119 1, European Pharmacopoeia, and 
United States Pharmacopoeia all contain monographs covering the 
requirements to evaluate pressurised metered dose inhaler systems. 
Methods are described for analysing the respirable fraction and the 
emitted dose, but not to describe the particle size distribution within 
the aerosol cloud. For these tests the air flow rate through the 
apparatus is set at I litre per second with a continuous air flow 
through the apparatus. No standard monograph exists at present for 
the evaluation of dry powder inhaler systems. 
All dry powder inhalers are, by design, breath actuated. Upon 
inspiration the patient creates a pressure drop across the device in 
order to create an air flow through it. An inherent resistance to the 
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passage of air through the device is necessary to create the turbulent 
airflow which fluidises and disperses the dose of drug. This resistance 
is unique to each device [ 1251. Therefore, testing devices at a constant 
air flow rate necessitates a range of pressure drops for a variety of 
devices. Conversely, a constant pressure drop across all dry powder 
inhalation systems results in a variety of air flow rates, depending on 
the device. 
Valuable data for the clinical performance of an inhalation 
system can be provided by the determination of the pressure drop 
against the flow rate [1251. This is because the inspiratory effort 
required from the patient to deliver the dose is directly proportional to 
the pressure drop [ 14 1. Without a standard monograph comparisons of 
dry powder inhalation devices are difficult due to the many different 
experimental methods employed, few of which consider the inspiratory 
effort. 
4.2.8. b Data 
The size distribution of particles present in an aerosol cloud can 
be described by the Mass Median Aerodynamic Diameter and the 
Geometric Standard Deviation. Recommendations have been made for 
values of these parameters which would achieve optimal lung delivery 
of the drug [ 1241. 
The mass distribution of drug throughout the apparatus is used 
to determine the particle size distribution in the aerosol. Several factors 
can produce errors in this determination. These are: lactose carrying 
drug particles deposited in calibrated 'throat' sections and Ist stages; 
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particle 'bounce off associated with overloaded stages; wall deposition 
caused by interception of particles which remain airborne after passing 
the impaction plate, and increased later stage deposition due to non- 
spherical particles. 
Particles attached to lactose 
Carrier particles as well as drug are discharged from inhalation 
devices which use powder mixes. In theory all of the drug particles are 
removed from the surface of the carrier. The carrier particles, because 
of their size are impacted onto the pre-separator and Ist stage of the 
apparatus. It has been shown that some drug particles remain attached 
to the carrier particles [ 126 1. This implies that the mass deposition of 
drug in the pre-separator and lst stage is due to large drug aggregates 
and drug which is attached to the carrier. Particle size determination is 
then biased towards the larger particles and is not a true 
representation of the powder cloud. 
Bounce off 
As previously mentioned impaction plates may become 
overloaded. This is due to a very high number of particles being 
collected on the stage. It is possible that particles with an aerodynamic 
diameter greater than the effective cut off diameter for a stage may 
become impacted, but subsequently removed from the stage due to 
'bounce off or 'blow off [ 1081. The particles then pass into the later 
stages of the apparatus where they are deposited. Therefore particles 
with a larger mass than the calibration values determine can be present 




The deflection of the air stream due to the position of the 
impaction plate is the point where particles are deposited due to their 
size. The air stream then flows through the next jet into the proceeding 
stage of the apparatus. The turbulent air flow within the stage causes 
drug particle to become deposited on the walls of the stage [98,1081. 
According to the type of impactor used the errors incurred when 
particle sizing are different in nature. Impaction plates are removed 
from dry stage impactors and assayed for drug. The drug remaining on 
the walls of the stage is unaccounted for. This fraction of the particle 
cloud consists of increasingly smaller sized particles which are not 
impacted onto the plates. Therefore the overall cloud loses a proportion 
of the smaller sized particles. This effect is slightly different with wet 
stage impactors. Analysis of deposited drug in these instruments 
involves washing out the entire stage to collect drug not only impacted 
on the plates, but all of the internal surfaces. Therefore the wall 
deposits increase the mass of drug collected at each stage, although the 
particle sizes are smaller than the effective cut off diameter. Both effects 
lead to a size determination which is not a true representation of the 
powder cloud. 
Non-spherical particles 
Particles which are not spherical, particularly those with acicular 
structure, have aerodynamic diameters with a very weak dependence 
on the length [ 1271. Particles with very small aerodynamic diameters 
and a needle-like shape carry a much larger drug mass than 
Page 147 
Chapter Four 
isodiametric particles [6]. When the lower stages of impinger apparatus 
are assayed the particle sizing towards the smaller sizes will be biased. 
Therefore the determination of drug particle size distributions 
ftom dry powder inhalation systems incurs many errors. Added to this 
is the knowledge that different inertial separators yield different values 
for Mass Median Aerodynamic Diameter of an aerosol cloud from the 
same device [981. Using different collection surfaces within the same 
instrument also gives rise to different determinations of Mass Median 
Aerodynamic Diameter [971. 
Inertial impactors are useful instruments to determine the 
deposition of drug from an inhalation system. The particle size 
distribution can be determined for the particles of drug within the 
emitted dose. The size and distribution can then be described by the 
Mass Median Aerodynamic Diameter and Geometric Standard Deviation 
of particles within the cloud. It is assumed in the determination, 
however, that the drug particles behave in a similar manner to the 
calibration material used for the apparatus. This, of course is not 
always the case. 
Without determining an absolute value, the regional deposition of 
drug particles can be expressed as the respirable fraction. The mass of 
drug from the powder cloud considered possible to penetrate and be 
deposited in the small branching airways of the lungs can be evaluated 
from deposition within particular stages of separation apparatus. 
Evaluation of the effect on deposition caused by changes to the 
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inhalation system can be carried out by direct comparison of the drug 




A multi-stage liquid impinger was used as an in-vitro model to 
assess the drug deposition characteristics from the binary powder 
mixtures. The inhaler device was developed at the Rijksuniversiteit 
Groningen, the Netherlands. 
4.4 Materials 
The following binary powder mixes were tested to evaluate their 
deposition proffle. 







0.4 124 40 
Reproterol 0.15 1.5 





4.4.1. Multi-stage liquid impinger 
The multi-stage liquid impinger is constructed of glass with sintered 
glass impaction plates. Based upon May's design [ 109 1, the apparatus 









Figure 4.4.1 Diagram showing multi-stage liquid impinger 
A tubular glass induction port with a 90' bend was used to 
simulate the oro-pharynx. 
4.4.2. Inhaler device 
The inhaler device used was a prototype of a cyclone type inhaler. 





chamber. During the inhalation cycle air is drawn into this chamber 
through two tangential inlets. The fluidised drug then leaves the 
chamber with the air stream which travels via the mouthpiece into the 
n-julti-stage liquid impinger. The particles of excipient, because of their 
larger size, do not undergo pneumatic transport, and remain in the 
cyclone chamber after the inhalation cycle. 
The inhaler device was constructed from stainless steel except for 
the brass base of the cyclone chamber and the PTFE mouthpiece. 
Sample and air inlet 
30 
Plan view Cross section 
Figure 4.4.2 Inhaler device 
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4.5 Methods 
4.5.1 Air flow calibration 
Air flow through the inhaler device and impaction apparatus was 
determined with respect to the pressure drop across the device. 
Calibration of the apparatus to the pressure drop relating to 1 L. sec-1 
flow rate proceeded experimental analysis. 
4.5.2 Multi-stage liquid impinger analysis 
The multi-stage liquid impinger was clean and dry and 
equilibrated at room temperature. Using a pipette, 20 mL of deionised 
water was introduced to each stage through the access port. This was 
sufficient to moisten the impaction plates. The access port was sealed 
with a screw cap. The apparatus was assembled as shown in Figure 
4.5.1. 
The mouthpiece of the inhalation device was orientated in such a 
way that the air entered the device only via the cyclone chamber. The 
brass bottom of the cyclone chamber was connected to earth. 
The air flow through the apparatus was adjusted using the air 
flow regulator until the pressure drop across the inhaler device reached 
the calibrated value corresponding to I litre per second volumetric flow 
rate. 
A single 25 mg dose of powder mix, previously weighed using a 
Mettler AT261 balance, was transferred into the cyclone chamber 





The three-way tap was orientated such that the air flow was 
routed through the apparatus. The inspiration was six seconds in 
duration. 
The inhaler device was then removed from the connecting piece, 
the mouthpiece carefully disconnected, and the particles from the dose 
which remained in the cyclone chamber tapped into a tared glass 
beaker. 
The device was reassembled and replaced in the connecting piece. 
This procedure was repeated nine times for each analysis. 
When the last inhalation cycle was completed the components of 
the apparatus were washed with deionised water. The drug was 
collected in this way from the cyclone chamber, mouthpiece and pre- 
separator. The solutions were collected in glass beakers. 
The impinger was then disconnected and the fourth stage sealed 
with a screw cap. The instrument was then agitated in such a way that 
the impaction plates and walls of each stage were washed with the 
solutions. Care was taken that no solution passed from one stage to 
another during the agitation. 
The solutions were then transferred from the stages into glass 
beakers. The apparatus was agitated more vigorously when solution 
was remaining in stage 4 only. This was to ensure that all of the 




The total mass of powder which had been removed from the 
cyclone chamber after each inspiration was recorded. Sufficient 
deionised water was then added to this residue in order to dissolve both 
the drug and the lactose. 
4.5.3 Drug assay 
Solutions were assayed for drug content using the UN assay 
described in section 2.11. There was no interference at the absorption 




Deposition profiles were constructed for each of the powder blends. 
Drug was recovered from the following locations: 
i. cyclone chamber 
Ii. mouthpiece 
iii. pre-separator (throat) 
iv. stage 1 
V. stage 2 
vi. stage 3 
vi. stage 4 
viii. attached to the lactose residue removed from the cyclone 
Qualitative analysis of the powder residue which remained in the 
inhaler was carried out by image analysis and scanning electron 
microscopy. 
4.6.1 Deposition profiles 
The data obtained from each impinger analysis are expressed in the 
form of deposition profiles. The drug recovered at each location is 
expressed as a percentage of the total drug loaded into the inhalation 
device during the analysis. 
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The data collected from the multi-stage liquid impinger can be 
presented in a number of ways. The mass of drug recovered at each 
location of the inhalation apparatus may be expressed as: 
a) a percentage of the drug loaded into the inhalation device 
This value provides a means of analysis of the whole inhalation 
and powder system as a drug delivery system. It also takes into account 
analytical technique. The recovery from every experiment carried out 
was below 100% of the loaded dose. This may be due to unrecovered 
drug remaining on the upper surface of each stage of the multi-stage 
liquid impinger, in the jets which connect each stage of the apparatus, 
and any drug which may have left stage 4; 
b) a percentage of the recovered drug 
This evaluates the whole system as above, but adjusts for the 
unrecovered drug; 
c) a percentage of the emitted dose 
This value is used for the portions of the dose which are collected 
from the aerosol cloud. The 100% value is taken as the sum of the 
throat section plus stages I to 4 of the multi-stage liquid impinger 
apparatus. This allows analysis of the aerosol cloud, and evaluates the 
composition of the fraction of the dose which is available for inhalation 
bY the patient. 
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Analysis of the deposition results gives an indication of- 
i-the role of adhesion within the powder mixes, and its influence on 
drug deposition; 
ii- the role of cohesion within the powder mixes, and its influence on 
drug deposition; 
iii- the consequent effect on the efficiency of the system to deliver drug 
to the target site; 
iv- a comparison of the performance of powder mixes containing 




4.7.2 The role of adhesion within the powder mixes, and 
its influence on drug deposition 
Adhesion is responsible for the direct association between the 
drug species and carrier particles in the powder mix. This adhesion 
maintains the integrity of the mix and prevents segregation of active 
and carrier particles. The inhaler device was designed such that the 
carrier particles of the dose are retained during the inhalation cycle. 
Analysis of this powder residue allowed the quantification of drug which 
was not detached during the air flow through the device. Drug which 
remained adhered was assayed using UV spectroscopy. Scanning 
electron microscopy was employed in order to analyse visually this 
portion of the dose. 
4.7.2. i UV assay of drug remaining adhered 
The residue powder was dissolved in double distilled water and 
assayed for drug content as described in Section 2.11. The percentage 
w/w of drug in the powder mix remaining in the device post inhalation 
was determined for each powder blend. The data from the 
quantification of this residue mix are presented in Table 4.7.1 and 




Nedocromil sodium Sodium cromoglycate Rep roterol 
iriitial mix Residue mix initial mix 
_ 
Residue mix Initial mix Residue mix 
concentration concentration concentration concentration concentration concentration 
(%W/W) (%w/w) (%w/w) (%w/w) (%W/W) (%w/w) 
0.392 0.171 0.394 0.097 0.150 0.050 
0.985 0.381 0.960 0.225 1.475 0.330 
1.956 1.205 1.951 0.430 
3.908 1.317 3.704 0.449 
Table 4.7.1 %w/w drug content of mix residue after inhalation 
Powder mix concentration after inhalation against powder 
mix concentration before inhalation 
0.0 
III 
1.0 2.0 3.0 4.0 
w/w initial mix 
Drug species: 0 nedocromil sodium v reproterol 
0 sodium cromoglycate 
Figure 4.7.1 Relationship between %w/w initial powder mix and %w/w 
residue powder mix for three different drug species mixed with lactose 
The error bars represent the standard deviation of the data. 
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The graph shows that an increasing mass of arug is I-e-LaII-jeu c)jj 
the lactose particles as the drug load in the initial mix increases. The 
number of adhered particles appears to reach a maximum as the %w/w 
concentration of the retained mix does not dramatically increase 
between the values of 2 %w/w and 4 %w/w initial drug mix. 
Scanning electron micrographs of the powder mixes at 4 %w/ , \, 
drug concentration pre and post inhalation show the distribution of the 
drug particles. The surface of the carrier particles in the pre inhalation 
mixes accommodate both single particles and small aggregates of 
drug. 
These can be identified in Figures 4.7.2 and 4.7.3 for mixes of 
nedocromil sodium and sodium cromoglycate at 
4 %w/w nominal drug 
concentration. The distribution of these adhered aggregates 
throughout 
the initial mixes can be seen in the image analysis photographs, 
reproduced in Figures 3.6.4 to 3.6.16. 
Figure 4.7.2. Scanning electron micrograph of nedocromil 
sodium/lactose powder mix 4.0 %w/w drug concentration. 
Picture 
number 0695. 
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Figure 4.7.3. Scanning electron micrograph of sodium 
cromoglycate /lactose powder mix 4.0 %w/w drug concentration. 
Picture number 0694. 
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Particles of drug can be identified on the surface of the carrier 
particles which were recovered from the device after the inhalation 
cycle. The adhered drug which has not been removed from the carrier 
exists as single isolated particles, or very small clusters of a few drug 
particles. These can be seen in the scanning electron micrographs 
reproduced in Figures 4.7.4 to 4.7.6. The larger aggregates which were 
associated with the carrier in the pre-inhalation mix are no longer 
present. Therefore, the drug which fluidises and leaves the cyclone 
chamber derives mainly from these surface held drug aggregates. 
Figure 4.7.4. Scanning electron micrograph of nedocromil 
sodium/lactose powder residue after inhalation. Picture number 0692. 
Chapter Four 
Figure 4.7.5. Scanning electron micrograph of sodium 
cromoglycate /lactose powder residue after inhalation. 
Picture number 069 1. 
Figure 4.7.6. Scanning electron micrograph of sodium 
cromoglycate /lactose powder residue after inhalation. 
Picture number 069 1. 
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The percent remaining adhered to the lactose at an initial drug 
concentration of 40 %w/w was not determined. The composition of the 
binary mix pre-inhalation was such that it contained non-adhered drug 
agglomerates. Visual inspection of the powder remaining in the cyclone 
chamber post-inhalation determined that some of these agglomerates 
were still present. Therefore U. V. assay of this remaining powder mix 
would not provide information relating to the mass of drug which 
remained adhered to the carrier during the inspiration cycle. 
Scanning electron microscopy was carried out on these post- 
inhalation particles in order to analyse visually the surface of the carrier 
particles. The resultant photornicrographs from the nedocromil sodium 
and sodium cromoglycate 40 %w/w mixes are reproduced in Figures 
4.7.7 and 4.7.8 respectively. 
Figure 4.7.7. Scanning electron micrograph of nedocromil 
sodium/lactose powder residue from 40 %w/w drug mix after inhalation. 
Picture number 1949. 
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Figure 4.7.8. Scanning electron micrograph of sodium 
cromoglycate/ lactose powder residue from 
40 % w/w drug mix after 
inhalation. Picture number 2070. 
The residue lactose particles from these 
40 %w/w mixes have, 
associated with their surface, both single 
drug particles and small 
adhered aggregates. These aggregates appear much 
larger than the 
small clusters seen attached to the carrier particles 
of the lower 
concentration mixes. When compared with 
those which were adhered in 
the mix pre-inhalation, they are considerably smaller 
as shown in 
figures 4.7.9 and 4.7.10. 
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Figure 4.7.9. Scanning electron micrograph of nedocromil 
sodium/lactose 40 % w/w drug mix. Picture number 
2204. 
Figure 4.7.10. Scanning electron micrograph of sodium 
cromoglycate /lactose 40 % w/w drug mix. Picture number 
2060. 
Therefore it can be concluded that the energy supplied 
by the act of 
inspiration is not sufficient to remove all of the adhered 
drug. Drug 




ag regates which are present in the powder mix. This suggests that the rýg 
drug-lactose adhesive interactions are stronger than the drug-drug 
cohesive interactions. 
As discussed previously in section 3.2 mechanisms of adhesion 
include van der Waals' forces, electrostatic forces and mechanical 
interlocking as well as forces due to liquid bridges, solid bridges and 
magnetic moments. The extent of the adhesive interactions within the 
binary powder mixes may be due to a combination of the electrostatic 
and van der Waals' forces. 
During the mixing process contacts between surfaces of particles 
in the mix will occur, and also be broken. When this process occurs 
between two dissimilar materials static electrification, otherwise known 
as triboelectrification results. The triboelectrification of the two 
dissimilar surfaces in mutual contact occurs by transfer of electrons 
from one material to another [ 1291 Therefore, the particles which 
experience contact events with carrier particles and the mixing vessel 
are able to form point charges on their surfaces. The strongly adhered 
drug particles may result from the electrostatic attractions between 
drug and lactose facilitating close particle contact which leads to 
increased van der Waals' interactions. 
Triboelectrification may also cause the formation of the loosely 
packed cohesive aggregates. The large surface energy inherent to the 
small drug particles increases the cohesive tendency. Like-charging of 
these drug particles will cause a barrier for interparticle contact, 
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resulting in less opportunity for the van der Waal's forces to form 




4.7.3 The influence of adhesion upon the deposition 
Profile 
The deposition of drug from the powder formulation is affected by 
the adhesion between the drug and carrier particles. Because a 
proportion of drug remains attached to the carrier it is not possible to 
deliver 100% of the loaded dose (as described in section 4.6) as a 
powder cloud. The reduction of the emitted dose (as described in 
section 4.6), therefore, decreases the performance of the inhalation 
system. The particles of drug which remain attached to the carrier are 
single entities, or very small clusters. If they were released from the 
carrier, these particles would be included in the respirable fraction of 
the dose. Therefore, it Is suggested that the adhesion exhibited in the 
drug/carrier interactive unit, which is not disrupted during the 
inhalation cycle, adheres drug particles at the expense of the respirable 
fraction. 
When expressed as a percentage of the recovered dose (as 
described in section 4.6), the reduction in the emitted dose can be 
expressed, as shown in Tables 4.7.1,4.7.2,4.7.3 and Figures 4.7.11, 




0 Nedocromil sodium 
Percentage of recovered drug from each location 
Drug conc. mouth & powder cloud lactose 
(%w/w) cyclone (0/0) 
0.4 14.50 39.70 45.80 
1.0 15.54 45.87 38.59 
2.0 12.47 39.17 48.37 
4.0 17.58 49.42 33.01 




mouth & cyclone aerosol cloud lactose 
Location 
0.4 % w/w drug concentration 2.0 % w/w drug concentration 
1.0 % w/w drug concentration 4.0 % w/w drug concentration 
Figure 4.7.11 Percentage distribution of the recovered drug from Mixes 
of nedocromil sodium and lactose 
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Sodium cromoglycate 
Percenta ge of recovered drug from each location 
Drug conc. mouth & powder cloud lactose 
(%w/w) cyclone (0/0) 
0.4 16.21 58.36 25.43 
1.0 23.45 55.27 21.28 
2.0 16.76 59.45 23.79 
4.0 38.73 48.91 12.37 
Table 4.7.2 Distribution of recovered drug from sodium cromoglycate 
powder mixes 
Sodium cromoglycate 
mouth & cyclone aerosol cloud 
Location 
lactose 
[ý] 0.4 % w/w drug concentration 10 2.0 % w/w drug concentration 
J! 2 1.0 % w/w drug concentration 0 4.0 % w/w drug concentration 
Figure 4.7.12 Percentage distribution of the recovered drug from mixes 
of sodium cromoglycate and lactose 
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Reproterol 
Percentag e of recovered drug from each location 
Drug conc. mouth & powder cloud lactose 
(%W/W) cyclone (0/0) 
0.15 27.44 34.52 38.04 
1.5 1 31.46 46.45 22.09 













*% %1 %6 








0.15 % w/w drug concentration Q 1.5 % w/w drug concentration 
Figure 4.7.13 Percentage distribution of the recovered drug from mixes 
of reproterol and lactose 
A constant mass of drug remains adhered to the carrier particles 
at 2 %w/w and 4 %w/w drug load for the mixes containing nedocrornil 
sodium and sodium cromoglycate as the drug species(Figure 4.7. U. 
This is reflected by the percentage of the recovered dose due to drug 
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remaining adhered to the lactose particles decreasing at the higher 
concentration. An increase in mouthpiece deposition from sodium 
cromoglycate 4 %w/w drug concentration occurs at the expense of the 
emitted dose. This indicates an attractive interaction between the 
sodium cromoglycate particles and the surface of the mouthpiece that 
does not occur to such an extent for nedocromil sodium. 
Therefore an effect of the adhesive interactions within the powder 
mixes is to decrease the respirable fraction of the drug. The results 
suggest that there is a finite number of sites for adhesion on the lactose 
surface, which is drug specific, or, a finite number of drug particles are 
able to take part in the adhesive interactions. A degree of competition 
between the adhesive and cohesive interactions of drug particles may 
be responsible for the limit of drug/lactose interactions. 
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4.7.5 The role of cohesion within the powder mixes, and 
its influence on drug deposition 
The cohesive nature of the active species in the powder mix is 
responsible for the maintenance of the drug aggregates. The majority of 
these aggregates become airborne and leave the cyclone chamber. 
Deposition of the drug contained in these aggregates is dependent upon 
whether or not they disperse into primary particles. The aggregates 
which do not disperse will not travel to the stages of the multi-stage 
liquid impinger that correspond to reaching the target site. Because of 
their large size, these drug clusters will be deposited in the throat and 
stage I of the In vitro inhalation apparatus and therefore not reach the 
respiratory zone In vivo. 
Drug deposition at these locations may also be due to the loss of 
carrier particles from the cyclone chamber of the device. As determined 
previously, some drug remains adhered to the carrier particles during 
the inhalation cycle. These particles of lactose have travelled with the 
air stream having been subjected to the cyclone effect within the 
chamber. Therefore, the drug associated with this fraction of the carrier 
Particles will correspond to the concentration of drug which remains 
attached to the residue particles after the inhalation cycle. The values 
determined for the mass of lactose leaving the inhalation device and the 
associated drug are reproduced below. 
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Drug mix Mass of Mean %w/w Mass of associated 
%W/W lactose lost rem aining mix drug (mg) 
from 10 (±sd) (±sd) 
doses (mg). 
(±sd) 
mixes of nedocromil sodium 
0.4% 19.16 (±7.0) 0.17 (±0.02 
j 
3.24 x 10 -5 
(±I. 1X 10-5) 
1% 13.05 (±1.5) 0.38 (±0.3) 4.94 x 10 -5 (±2.5 X 10-6) 
2% 20.00 (±8.9) 1.21 (±0.2) 2.45 X 10 -4 (±1.4x 10-4) 
4% 15.16 (±3.2) 1.31 (±0.2) 2.03 x 
10 -4 (±6.5 x 
10-5) 
Mixes of sodium cromogly ate 
0.4% 10.85 (±0.2) 0.09 (±0.01) 1.05xIO -5 (±6.1 X 10-7) 
1% 14.98 (±4.4) 0.22 (±0.04) 3.31 x 
10 `5 (±7.6 X 10-6) 
2% 16.11 (±5.2) 0.48 (±O. I) 7.90xlO -5 (±4.2 X 10-5) 
4% 20.96 (±12.8) 0.45 (±0.01) 9.48 x 
10 `5 (±5.9 x 
10-5) 
40% 6.06 (±2.2) 
1 
3.08 (±I. O) 
11.75 
X 10 -4 (±3.6 x 
10-5) 
Mixes of reproterol 
0.15% 22.08 (±12.6) 0.05 (±4.5 X 10-3) 1.16 x 
10 -5 (±7.7 X 10-6) 
1 1.5% 12.48 (±1.2) 0.33 (±0.04) 1 4.09 X_10 -5 (±3.5 X 10 -6 )_j 
Table 4.7.4 Drug deposition in the throat and stage I of the multi-stage 
liquid impinger apparatus due to adhesion to lactose 
When expressed as a percentage of the drug deposition by mass 
at the throat and stage 1, the largest value calculated was 0.08 %. The 
error therefore incurred due to lactose deposition in the impinger 
apparatus was considered to be negligible. 
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The sum of the throat and stage I deposition can be expressed 
both as a percentage of the drug loaded into the device, and a 
percentage of the emitted dose. Figures 4.7.14,4.7.15 and 4.7.16 show 
the aggregate fractions recovered ftom the nedocromil sodium, sodium 
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When expressed as a percentage of the loaded dose, the aggregate 
deposition tends to Increase with an increasing drug load in the mix. 
Therefore an increasing proportion of drug in the mix is in the form of 
cohesive aggregates which become detached from the carrier particles 
but do not deaggregate during the inspiration cycle. This suggests that 
with an increasing mass of drug in the binary mix, there is an 
increasing tendency to form this type of aggregate. 
The small deposition of the aggregate fraction from the 40 %w/w 
mix when expressed as a percentage of the loaded dose is due to the 
very high mouthpiece deposition of the drug. 
When expressed as a percentage of the emitted dose the 
aggregate fraction tends to increase with an increase in drug load up to 
2 %w/w. There is no further increase of this fraction between 2 %w/w 
and 4 %w/w for nedocromil sodium, and between 2 %w/w and 
40 %w/w for sodium cromoglycate. Therefore, of the drug which forms 
the aerosol cloud, the proportion of non-dispersing drug aggregates 
increases with the drug load. Above drug concentrations of 2 %w/w 
this proportion tends to be constant and independent of the drug load. 
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4.7.6 The consequent effect of adhesion and cohesion on 
the efficiency of the system to deliver drug to the target 
site 
Drug particles which account for the respirable fraction of the 
dose are deposited on stages 3 and 4 of the multi-stage liquid impinger. 
In order to travel through the apparatus to these stages the particles 
must be airborne as single entities. 
The adhesive and cohesive interactions which occur within the 
powder mix combine to have an effect on the respirable fraction. 
This respirable fraction can be expressed both as a percentage of 
the drug loaded into the device, and as a percentage of the emitted 
dose. 
Figures 4.7.17,4.7.18 and 4.7.19 show the respirable fractions 
recovered from the nedocromil sodium, sodium cromoglycate and 
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When expressed as a percentage of the loaded dose, the 
respirable fraction appears to be independent of the drug 
concentration. This suggests that a constant amount of the drug in 
each mix is fluidised as single particles. This is due to the combined 
effect of a decreasing proportion of drug remaining adhered to the 
carrier after the inhalation cycle, and an increasing proportion existing 
as non-dispersing aggregates, as the drug load increases. 
The small respirable fraction from the 40 %w/w mix when 
expressed as a percentage of the loaded dose is due to the high 
mouthpiece deposition of the drug. 
When expressed as a percentage of the emitted dose the 
respirable fraction tends to decrease with an increase in the drug load 
up to 2 %w/w concentration. There is no further decrease in this 
fraction between 2 %w/w and 4 %w/w for nedocromil sodium and 
2 %w/w and 40 %w/w for sodium cromoglycate. 
The behaviour of the respirable portion of the aerosol cloud is a 
reflection of the cohesive interactions which produce non-dispersing 
aggregates. As the proportion of the drug which exists in these 
aggregates increases, then the respirable fraction of the cloud 
decreases. 
For mixes of nedocromil sodium and sodium cromoglycate with 
lactose the ratio of the respirable fraction to the aggregate fraction 
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4.7.7 Effect of type of drug 
Adhesive interactions 
A significant difference exists when comparing the masses of drug 
adhered to the carrier particles at 2 %w/w and 4 %w/w for nedocromil 
sodium and sodium cromoglycate. Both drug species show a saturated 
effect at 2 %, but the mass of nedocromil sodium retained on the 
carrier surface is much greater than the corresponding mass of sodium 
cromoglycate. As the photomicrographs of the remaining fraction post 
inhalation show, the surface of the carrier particles from the nedocromil 
sodium powder mix contains more drug particles, covering a larger 
proportion of the lactose surface than in the sodium cromoglycate 
residue. Therefore the difference lies in a greater number of single 
particles remaining adhered, rather than stronger cohesive interactions 
which would cause aggregates to be retained on the lactose surface. 
The photomicrographs of the powder mixes containing nedocromil 
sodium and sodium cromoglycate show similar structures within the 
mix. Therefore the resultant difference in amount of drug remaining 
adhered is due to the difference in magnitude between the adhesive 
interactions of lactose and nedocromil sodium, and lactose and sodium 
cromoglycate. 
Emitted dose composition 
Considering the drug deposition as fractions of the emitted dose 
allows a comparison of the cloud composition of powder doses. The 
difference in adhesion behaviour between nedocromil sodium and 
sodium cromoglycate do not affect these values. The deposition 
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characteristics of the aerosol cloud from both types of mix are similar, 
as shown in Tables 4.7.5 and 4.7.6. 
Drug concentration Nedocromil sodium 
powder mixes (%) 
Sodium cromoglycate 
powder mixes (%) 
0.4 % w/w 72.19 72.36 
1.0 % W/W 64.36 62.52 
2.0 % w/w 45.73 47.79 
4.0 % w/w 45.04 52.14 
Table 4.7.5 Respirable fraction as a percentage of the emitted dose 
Drug concentration Nedocromil sodium 
powder mixes (%) 
Sodium cromoglycate 
powder mixes M) 
0.4 % w/w 25.14 23.61 
1.0 % W/W 31.27 32.49 
2.0 % w/w 48.52 44.85 
4.0 % w/w 46.68 41.37 
Table 4.7.6 Aggregate fraction as a percentage of the emitted dose 
These results are in contrast with mixes of reproterol, as shown below. 
Drug concentration Respirable fraction as Aggregate fraction as 
a percentage of the a percentage of the 
emitted dose M emitted dose M 
0.15 % w/w 91.53 14.88 
1 1.5 % w/w 1 82.67 1 13.89 




As shown in Chapter Two, nedocromil sodium and sodium 
cromoglycate are very similar with respect to size, shape and surface 
area. The performance of the powder blends of lactose with nedocromil 
sodium and sodium cromoglycate as inhalation dosage forms suggests 
that both species have a similar balance of adhesive /cohesive 
interactions, of a similar magnitude. The difference in the number of 
particles remaining adhered after inhalation may be due either to a 
difference in recognition of sites for adhesion, or different electrostatic 
behaviour. The difference in adhesion behaviour has no effect on the 
generation of the respirable fraction from the dose, which suggests that 
this portion of the powder cloud is cohesion dependent, rather than 
adhesion dependent. 
The surface held cohesive aggregates are therefore the source of 
the respirable fraction of the dose. The limited respirable fraction is a 
reflection of the structure of the powder mix. The structures observed 
in the mix include adhered single particles, adhered aggregates and 
non-adhered aggregates. A dynamic equilibrium may exist between 






adhered single paricles 
Figure 4.8.1 Structures within binary powder mixes 
Therefore it is suggested that in order to optimise the respirable 
fraction of a powder dose manipulation of the structure of the mix 
towards the state of adhered aggregates would be favourable. 
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As a result of determining the structure of binary interactive 
mixes used in inhalation therapy it was apparent, as reported in 
Chapter 3, that some form of competition takes place between the drug- 
carrier adhesion and the drug-drug cohesion interactions. As reported 
in Chapter 4, these interactions influence the delivery of drug to the 
lower lung. 
Therefore it was decided to investigate and attempt to quantify 
the magnitudes of these interactions. 
The aim of this chapter was to elucidate the magnitude of the 
adhesive interactions between lactose carrier particles and nedocromil 
sodium. This was done by the development of a novel method based on 
an ultracentrifuge technique. 
5.2 Introduction 
A variety of methods employing the ultracentrifuge have recently 
been developed in order to quantify a force of adhesion associated with 
small particles. The ultracentrifuge method uses the principle that the 
magnitude of an induced centrifugal force which removes a powder 
particle from a substrate is equal to the attractive forces which e)ý: isted 
between that particle and the substrate. 
A centrifugal force is experienced by bodies which rotate around 
a central point. This force is directed outwards from the centre of 
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rotation, through the centre of gravity of the body. Newton's Second 
Law states that 
Force = mass x acceleration (equation 5.2.1) 
In the case of centripetal force ( which is directed towards the centre of 
the circle) 
F= force acting upon the body (N) 
m= mass of the particle (kg) 
a= centripetal acceleration (rad. sec-') 
The centripetal acceleration is the rate of change of velocity. This 
can be expressed as shown in equation 5.2.2. 
2 
a=r. w (equation 5.2.2) 
where r= distance between the centre of the particle and the 
a)ds of rotation (m) 
to = angular speed (rad. sec-') 
Therefore, the force experienced by a particle which maintains its 
motion in a circle, can be describe by equation 5.2.3. 
F=m. r. to 
2 (equation 5.2.3) 
If the force experienced by a particle is not sufficient to maintain 
the circular motion, the particle will assume a linear velocity in a 
direction tangential to the path of the circle. 
This principle has been applied to a number of systems. The 
interaction between small particles and a metal substrate was the first 
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to be examined [ 130]. The particles under investigation were dusted 
onto the substrate which was then placed into a centrifuge rotor. The 
substrate was orientated such that it was parallel to the vertical axis of 
rotation. The force experienced by the particles to detach them from the 
substrate was determined by the speed of rotation of the rotor in the 
centrifuge. This led to the determination of the relationship between the 
proportion of small particles remaining adhered to the metal substrate 
after experiencing the centrifugal force, and the magnitude of the force. 
A similar system has been used to evaluate the adhesion 
relationship between small metal spheres and a metal substrate f 13 1 ]. 
This technique was first applied to pharmaceutical systems in 
order to evaluate the adhesion which takes place during the handling 
and processing of pharmaceutical powders [1321. The adhesion 
behaviour of various pharmaceutical excipients was investigated using 
metal and polymer substrates. Interactions between a stainless steel 
substrate and pharmaceutical excipients have also been extensively 
studied [133-1351. 
The centrifuge principle has been applied to pharmaceutical 
powder mixes in order to investigate their tendency for segregation. A 
chamber, divided by a sieve screen replaced the plane substrate. Mixes 
of glass beads and active drug [ 136-1381, and mixes of pharmaceutical 
excipient and active drug [66,1391 were held behind the sieve screen in 
the chamber. Migration of the drug through the sieve into the collecting 




Distortion of the sieve screen at very high centrifuge speeds and 
accumulation of drug particles blocking the sieve apertures led to the 
development of a technique to evaluate species segregation from a 
single interactive unit [ 140,1411. The single interactive units were 
adhered to a substrate and the proportion of drug removed after each 
time in the centrifuge was determined using scanning electron 
microscopy. 
Analysis of data obtained from the centrifuge technique leads to 
the construction of an adhesion profile for the system under 
investigation. The ordinate of an adhesion profile relates to the 
percentage of drug which was not detached from the substrate during 
the time in the centrifuge. The abscissa is the magnitude of the force 
experienced by the particles. From this type of profile the median 
adhesion force (corresponding to 50 % retained drug) value can be 
determined (adhesion, %). This adhesion, % value can then be used to 
describe the adhesion behaviour of a system. The standard deviation of 
adhesion can also be derived. 
The standard deviation of adhesion was calculated by Kulvanich 
1361 from the relationship Cr = S2 
2 
where S is the rotor speed at 16/S50 16 
which 16% of the drug was retained on the carrier. This or value 
measures the scatter of minimum and maximum rotor speeds required 
to detach the drug particles. 
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0 5.3 Experimental 
A novel method was developed in this work which combined the 
plane substrate method as used by Krupp, Booth, St. John and Lam 
[130-1351 with the investigation of adhesion between drug-carrier 
interactive systems as studied by Staniforth and Kulvanich [66,136- 
1391. The method involved creating a powder covered plane substrate 
onto which carrier particles were dusted. 
This centrifuge method was used to evaluate adhesive 
interactions between nedocromil sodium and a -lactose monohydrate. 
The influence upon the adhesion proftle of impaction force, relative 
humidity and batch of nedocromil sodium were investigated. 
5.4 Materials 
The following materials were used. 
Sample Batch Number Preparation 
Nedocromil Sodium Z403V & ZBB9A Apex milled 
a-lactose 3217C Electromagnetic vibratory 
monohydrate sieved to collect size fraction 
63, um to 75, um, followed by 
hand brushing through a 
63 pm sieve to remove the 




A specially designed cell was constructed from aluminium. A 
plane surface faced an internal collection chamber. The cell was 
supported in a perspex holder such that this surface was parallel to the 
axis of rotation of the centrifuge. The cell could be placed either with 
the surface innermost to impact carrier particles, or outermost in which 
case the lactose particles would be removed from the nedocromil 
sodium surface by the centrifugal force. 
plane surface 
coRecting chamber 
Fig. 5.5.1 Centrifuge cell 
I 
Fig. 5.5.2 Orientation of the ceH within the ultracentrifuge rotor 
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The centrifuge rotor used was a 70Ti type used in a Beckman 




Image analysis was carried out using a Nikon SM-ZIO 
microscope, Hiatachi. CCTV with an Eltime Image III image analyser. 
5.6 Methods 
5.6.1 Preparation of the cell 
The plane surface of the centrifuge cell was coated with an 
adhesive solution prepared by dissolving clear adhesive tape in 
chloroform. Evaporation of the chloroform resulted in a tacky surface to 
which the drug powder, nedocromil sodium, could adhere. Sufficient 
drug was brushed through a 63 jzm sieve and allowed to fall on this 
tacky plane surface. This produced a continuous layer of the drug. The 
cell was assembled and placed in the centrifuge with the nedocromil 
sodium surface facing outermost. The assembly was spun for 1 minute 
at 20 000 revolutions per minute to remove any non-adhered drug. 
Visual analysis using the image analyser apparatus verifted that the 
disk surface had been successfully covered. 
A two layer sieve construction was used in order to achieve a 






75, urn sieve 




Fig. 5.6.1 Sieve assembly for lactose arrangement 
About 10 mg of lactose was brushed through the upper sieve. It 
was necessary for each lactose particle to locate itself within a pore of 
the lower sieve in order to come into contact with the drug surface. 
Therefore interpartic u late contact of the lactose particles could not 







5.6.2 Ultracentrifuge method 
Having prepared the plane surface as described above, the cell 
was carefully assembled and placed into the centrifuge rotor. The 
orientation of the cell was such that the lactose particles would 
experience a force to compress them onto the substrate surface. After a 
cycle at this impaction force, the cell was removed from the rotor and 
opened to expose the substrate. Image analysis was used to quantify 
the number of lactose particles present on the substrate. The cell was 
reassembled, and replaced in the rotor with the prepared surface facing 
outermost. The centrifugal force experienced by the particles of lactose 
this time was in the direction to remove them from the substrate. The 
rotor was held at the required speed for 60 seconds. After each time in 
the centrifuge the number of particles remaining on the disk was 
evaluated using image analysis. The cell was then replaced and spun at 




. described in equation 5.2.3 the force experienced by rotating 
bodies is proportional to the mass of the body, the centripetal 
acceleration. For a particle adhered to a substrate the centripetal force 
is provided by the force of adhesion between the two species. The 
particle becomes removed from the substrate when the adhesive force is 
not sufficient to maintain the particle in circular motion. This is 




t r. co (equation 5.7.1) 
The rotor speed of the centrifuge is related to the angular velocity 
as shown in equation 5.7.2. 
(o = (a/30) x rotor speed (equation 5.7.2) 
where the rotor speed is expressed in revolutions per minute. 
The working formula used to calculate the centrifugal force for 
this work is shown in equation 5.7.3. 
det 6 30 
2 
(equation 5.7.3) 
Where d is the particle diameter and p the density of the removed 
particle. 
The relative centrifugal force (FR. C. ) acting on the particles at the 
rotor speeds used can be calculated from equation 5.7.4. 
R. C. 
2 to . 
g 
(equation 5.7.4) 
A tabulation of the relative values for rotor speed, relative centrifugal 




(rev mhy 1) 
Relative centrifugal 
force (g) 
Adhesion force (N) 
1000 82.34 1.93 x 10-7 
1500 185.26 4.34x 10-7 
3000 741-03 1.74x 10-6 
5000 2058.41 4.82 x 
10-6 
10000 8233.62 1.93 x 10-'5 
15000 18525.65 4.34 x 10-5 
20000 32934.49 7.72 x 10-5 
25000 51460.14 1.21 X 10-4 
30000 74102.60 1.74x 10-4 
35000 100861.90 2.36 x 
10-4 
40000 131738.00 3.09 x 
10-4 
Table 5.7.1 Rotor speeds, Relative centrifugal force and Adhesion force 
for lactose particles in the centrifuge cell 
5.7.2 Effect of force of impaction 
Experimental analysis of the removal of lactose particles from the 
nedocromil sodium covered surface using the centrifuge technique was 
carried out. The samples were subjected to impaction forces ranging 
between 4.34 X 10-7 N (corresponding to 1 500 revolutions per minute of 
the centrifuge rotor) and 7.72xlO-'5N (corresponding to 20 000 
revolutions per minute of the centrifuge rotor). 
Testing was also carried out with no impaction of the lactose 
particles onto the nedocromil sodium covered surface. The lactose 
samples were simply brushed through the sieve arrangement as shown 
in Figure 5.6.1. The number of lactose particles on the surface was 
determined by image analysis. The cell was then assembled and placed 
in the centrifuge rotor orientated such that the centrifugal force would 
Page 202 
Chapter Five 
remove the particles of lactose from the nedocromil sodium covered 
surface. 
In order to ascertain whether the nedocromil sodium had covered 
the adhesive layer sufficiently to act as a barrier between the lactose 
particles and the adhesive layer, the proffle of lactose particles adhered 
directly to the adhesive layer was investigated. The particles of lactose 
were brushed through the sieve arrangement as shown in Figure 5.6.1. 
The number of lactose particles on the surface was determined by 
image analysis. The cell was then assembled and placed in the 
centrifuge rotor orientated such that the centrifugal force would remove 
the particles of lactose from the adhesive surface. 
Adhesion profiles for lactose particles on a nedocromil 
sodium powder substrate 
125% 
M0 









0.10 1.00 10.00 100.00 
Adhesion force (XIO-5N) 
Impaction forces: 4.3xl 0- 7N at 4.8xl 0- 6N 
0 1. gxlo- 5N4.3xlO-5N ---0- 7.7xjO-5N 
Figure 5.7.1 Effect of impaction force upon adhesion proffles 
Page 203 
Chapter Five 
The error bars represent the standard deviation of the data. 
The median adhesion force is the force at which 50% of the 
particles have been removed from the substrate surface. The respective 
median adhesion force (adhesion, %) for each Impaction force proffle are 
shown in Table 5.7.2. 
Impaction force (N) Measured 
adhesion..,, (N) 
4.34x 10-7 1.8 x 10-5 
4.82 x 10-6 5.4 x 10-5 
1.93 x 10-5 1.2 X 10-4 
4.34 x 10 -r' 1.2 X 10-4 
7.72 x 10`5 1.6 X 
10-4 
Table 5.7.2 Relationship between Impaction force and measured 
adhesion force 
Standard deviation values for the adhesion proffles are presented 
in Table 5.7.3. As described in section 5.2, the values 
S2 and 
S2 have 16 50 
been used to quantify the scatter of maximum and minimum rotor 
speeds required to detach the drug particles from a plane substrate. As 
seen in section 5.7, the force of adhesion (force of detachment) is 
directly proportional to the square of the rotor speed. The values of the 







This expresses the scatter of force required to detach the drug 
particles from the substrate. 
Impaction force (N) Standard deviation of 
adhesion (N) 
4.82 x 10-60 2.96 
1.93xlO-6 2.08 
4.34 x 10 1.85 
7.72 x 10 1.85 
Table 5.7.3 Standard deviation of adhesion data 
5.7.3 Discussion 
Table . 5.7.2 shows that the adhesion.... values tend to increase as 
the impaction force increases. There is a large scatter in the data. When 
statistically tested using ANOVAR two way analysis P<0.05, there is no 
significant difference between each data point for all the adhesion 
proffles. 
The interactions which are responsible for the lactose particles 
remaining associated with the surface of the disc after experiencing a 
force to remove them exist between the nedocromil sodium and lactose 
particles. The technique successfully covered the adhesive layer with 
nedocromil sodium. After experiencing a removal force of 7.72 X 10-5 N, 
100 % of the lactose particles remained adhered directly to the adhesive 
layer when no impaction force had been applied. This is in contrast 
with the removal of lactose particles from the nedocromil sodium 
covered surface when no impaction force was applied. In this case the 
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removal force 1-93x 10-7 N (corresponding to the slowest possible 
removal speed 1 000 revolutions per minute) was sufficient to remove 
all but 5% of the lactose particles. The system developed, therefore, 
could not determine a value for the adhesion behaviour between 
particles of lactose and a nedocromil sodium substrate without 
applying a force to impact the two species. 
Had the data been more reproducible, the construction of a plot 
of adhesion50% against the impaction force would have allowed 
extrapolation to the intercept of the ordinate. This would have 
determine the value for adhesion50% of a non-impacted system. 
The increase in adhesion50% values with an increasing impaction 
value may be due to deformation of the lactose particles, and distortion 
of the nedocromil sodium layer. 
The force applied during the impaction process increases the 
pressure at the points of contact between the lactose particle and the 
nedocromil sodium covered surface. This can lead to plastic 
deformation as the contacting surfaces are flattened [ 1331. The increase 
in the interfacial bonding areas would then lead to an increase in van 
der Waal's attractions. 
The bonding areas can increase in this case due to deformation of 
the adhesive and nedocromil. sodium layers. As the lactose particle 
Plastically deforms under the increased pressure, so do the layers on 
the disc. The result of such deformations is that the particle of lactose 









Figure 5.7.2 Representation of 'well, formation in the surface layers of 
the centrifuge disc 
These 'wells' were observed at locations on the nedocromil 
sodium surface which had accommodated particles of lactose. They 
were more obvious at the larger magnitude impaction forces. 
The combination of plastic deformation of the lactose particle and 
the layers covering the disc acts to increase the i nterpartic u late 
bonding area. The higher the applied force, the greater the extent of the 
deformation, and therefore the greater resultant adhesive force. This is 
shown by the tendency of the adhesion profiles to shift to the right with 
an increasing impaction force. 
Therefore the technique developed cannot provide an absolute 
value for the magnitude of the force of adhesion which exists between 




5.7.4 Investigation of change of relative humidity 
Monitoring of the laboratory relative humidity was carried out 
during the preparation of the discs for use with the ultracentrifuge 
technique. The mean relative humidity value was 49 %, with a range 
from 46.5 % to 52.4 %. The adhesion data did not exhibit any 
consistent relationship with the changing values of relative humidity 
within this range. However, when experimental work was carried out at 
a much lower relative humidity the following data was obtained. 
Adhesion profiles of lactose particles impacted at 7.7xlO-05 N 





t cu 75% ý 
8,: s4 40-4 t-4 
50%, 
Vf 4-J 









Adhesion force (xlO-5 N) 
100.0 
Relative humidity: --0-- 52.4%; .0 41.6% 
Figure 5.7.4 Effect of relative humidity upon impaction proffles 




Relative humidity (0/6) 52.4 41.6 
adhesion..,, (N) 1.06X 10-4 4.70x 10 
standard deviation of 1.89 2.07 
adhesion (N) 
Table 5.7.4 Effect of relative humidity 
5.7.5 Discussion 
The tendency for adhesion to increase with an increase in relative 
humidity has previously been observed using particle-plane systems 
[ 142,143 1, although the reverse has also been observed [ 138 1. 
High relative humidity causes a rapid dissipation of electrical 
charge accumulated on a material's surface. This can be attributed to 
an adsorbed moisture film on the material which causes an increase on 
conductivity of the material's surface and surrounding atmosphere 
[ 1441. Charge decay has been shown to be responsible for the decrease 
in adhesion tendency of interactive mixes during storage (1451. The 
adsorbed moisture film, however, can also be responsible for an 
increase of adhesion due to capillary interaction [1381. The relative 
humidity at which this capillary interaction occurs can be lower than 
the critical relative humidity at which liquid bridges are formed. 
Considering the system of lactose and nedocromil sodium it is 
suggested that the capillary force due to water condensation at the 
particle interface becomes more dominant than the associated loss of 
electrical activity. Therefore the adhesion tends to increase with an 
increase in relative humidity. 
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5.7.6 Effect of altering the batch of drug 
Batch variation of nedocromil sodium deposition in the 
multistage liquid impinger has been noted [1461. Centrifuge analysis 
was carried out to try and establish any difference of adhesion profile 
caused by altering the drug batch. The adhesion profile following 
impaction at 4.34 X 10-7 N was determined as shown in Figure 5.7.5. 
Adhesion profliles of lactose particles impacted at 7.7xIO-5 N 
onto a nedocromil sodium covered surface 
Adhesion force (xlO-5 N) 
Batch of drug: []-- Z403V-, 0 ZBB9A. 
Figure 5.7.5 Effect of batch variation upon adhesion proffle 
The two batches were run concurrently, therefore environmental 
conditions were identical during analysis. Values for the adhesion5o.,. 
and standard deviation of adhesion are shown in Table 5.7.5. 
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Drug batch Z403V ZBB9A 
adhesion., y . 
(N) I. Ix 10-5 X 10-6 3.1 
standard deviation of 2.67 2.45 
adhesion (N) 
Table 5.7.5 Effect of batch variation 
When tested statistically, the results at 5 000 and 10 000 revolutions 
per minute removal were significantly different. 
These results correlate with the findings that less drug from 
batch ZBB9A is deposited in stage 4 of the multistage liquid impinger, 
suggesting that more may be retained adhered to the lactose portion of 




A technique has been developed to attempt to quantify the force 
of adhesion between lactose particles and a substrate of drug particles. 
The results from this technique could be translated to the adhesive 
forces between drug particles and carrier particles within a binary 
powder mix used for inhalation therapy. However, the technique proved 
not to have the sensitivity capability to quantify these adhesive forces 
unless considerable force was applied to the system to encourage 
adhesion between the two powder species. This applied force distorted 
the system as it applied to binary powder mixes. 
The use of the ultracentrifuge technique has previously been 
used to identify adhesive interactions between pharmaceutical 
excipients and processing apparatus where such forces of impaction 
are justified, such as during tabletting [ 132,1331. When translated to 
the motion of the particles in a tumbling rotary mixer, a particle of 
lactose, to generate the same impaction force as generated in the 
ultracentrifuge system to achieve quantifiable adhesion would have to 
travel with an acceleration Of 
I. IX103 M. S-2 
. The action of the 
low 
energy mixer allows the particles to tumble under the force of gravity 
(9.81 M. S-2 ), and due to turbulent rotation of the vessel. This would 
not produce such a large acceleration. 
Therefore the system developed cannot provide absolute data 
relating to dry powder binary mixes prepared in a low energy mixer. 
However, when adhesion is enhanced, by impacting lactose particles 
onto the powder substrate, the method may be used as a tool to 
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distinguish differences in the adhesion behaviour of interacting 
systems, due to environmental or batch variation. 
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As a result of determining the structure of binary interactive 
mixes used in inhalation therapy it was apparent, as reported in 
Chapter 3, that some form of competition takes place between the drug- 
carrier adhesion and the drug-drug cohesion interactions. 
Therefore it was decided to Investigate and attempt to quantify 
the magnitudes of these interactions. 
The aim of this chapter was to elucidate the magnitude of the 
cohesive interactions between powder particles used in the formulation 
of these binary interactive mixes by the application of a cone 
penetrometry technique. 
This technique, novel to this area, was assessed for its suitability 




Cone penetration testing has been researched and developed 
primarily in the field of soil mechanics [ 147]. It has been used as a 
technique for measuring the mechanical properties of soils. This 
technology was transferred into the pharmaceutical sciences and used 
to investigate the measurement of the yield strength of pastes [1481. 
The application of a penetration test in powder mechanics followed 
[ 149], when it was assessed as a technique for measuring the cohesive 
strength of a powder. A reasonable correlation was observed between 
the penetrometer technique and a shear cell technique for the 
measurement of the cohesive caking strength of a powder. 
The technique involves driving a cone into a powder bed. The 
force required to drive the cone is measured as a function of the depth 
of penetration into the bed. The theory (below) shows that the 
penetration force at a given depth is proportional to the unconfined 
compression strength of the powder. 
6.2.1 Theory 
As a cone penetrates into a powder bed, the powder fails in shear 
in successive surfaces emanating from the tip of the cone (Figure 6.1). 
As the stress from the weight of powder above the failure zone is low, 
the failure is effectively unconfined. This appro. -dmation is very good 
when the powder strength is large relative to the stress due to the 





AL- - -- ---------- 
Figure 6.2.1 Failure surface for a cone penetrating an unconfined 
powder 
Using a container sufficiently large for the powder to be effectively 
unconfined, and a low penetration speed so that inertial effects can be 
neglected the force applied to the cone, F, can be determined relative to 
the penetration depth, d. 
The force applied to the cone is opposed by the frictional force 
Ff sbetween the cone and the powder, and the force required to cause 
failure of the powder under unconfined conditions, F,. 
F =Ff +Fc (equation 6.2.1) 
The frictional force can be taken to be proportional to the applied 
force through a coefficient af which is a function of the dynamic friction 
coefficient y for the cone-powder contact and the dynamic angle of 
internal friction of the powder Ok' 
Ff = af 
(M, Ok)F (equation 6.2.2) 
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Similarly, the force required to cause powder failure can be taken 
to be proportional to the unconfined compression strength of the 
powder specimen through a coefficient a, Itself a function ofy and 0., 
The force is related to the penetration depth, d, through a power index, 
n, which, in order to satisfy dimensions must be equal to 2. 
Fe = --c \1--, r JK I- 7d 
(141 Ok ) f/d' 
(equation 6.2.3) 
This unconfined compression strength is a measure of the 
cohesive interactions which e-Nist within the powder bed. 
Substituting equations 2 and 3 into equation 1, followed by 
rearrangement of the expression gives, 
F (equation 6.2-4) fc= af, ( y, Ok) d2 
For a given powder, af, should be constant over a range of 
stresses for whichy and0k are constant. It has been shown that values 
ofy and0k are similar for dissimilar powders [ 1491 suggesting that af, 
does not vary greatly from powder to powder. 
6.3 Materials 
The following materials were used. Kaolin and Starch 1500 were 




Sample Batch Number 
Nedocromil sodium 5B I 
Nedocromil. sodium 2002B I 
a-Lactose monohydrate(325 M) 3217C 
Light Kaolin B. P. 18CL 
Starch 1500 DM 486 
Table 6.3.1 Samples used for cone penetration testing 
Scanning electron micrographs of these samples have been made 
and are presented in section 2.3. 
6.4 Apparatus 
A specially designed and constructed apparatus was used to 
prepare the powder bed. The powder sample was contained in a glass 
dish 76 mm diameter and 65 mm. deep. The compaction apparatus is 
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The cone was constructed out of brass, had a half angle (a) of 5' 
and was 45 mm long. 
A Tensometer 10 (Monsanto) was used to drive the cone into the 
powder bed. The force was recorded continuously by a chart recorder. 
6.5 Methods 
The powder sample was loaded into the dish such that the top 
surface was level and the same height as the dish. The powder bed 
compaction apparatus was located on the dish. The appropriate mass 
was placed gently on the loading platform. After compaction for 
5 minutes the compaction apparatus was removed, and penetrometry 
tests carried out immediately. The cone was driven into the bed at a 
rate of 50 mm/min. Three penetration tests were carried out on each 
powder bed. The positions of the points of penetration were at half the 
radius and equidistant from each other, as shown in Figure 6.5.1. 




The relationships between the depth of penetration and the 
measured penetration force are shown in Figures 6.6.1 to 6.6.4. 
Nedocromil sodium Batch 5Bl 
3.0-1 
2.5 -ý 
0 10 20 30 50 
Depth of penetration (mm) 
Compaction stresses (Pa): N 6920; A 3460; 0 1730; 
865; 0 432. 
Figure 6.6.1 Relationship between force and depth of penetration into a 0 






Nedocromil sodium Batch 2002B1 
10 20 30 50 
Depth of penetration (mm) 
Compaction stresses (Pa) :0 6920; A 3460; 0 1730; 
865; 0 432. 
Figure 6.6.2 Relationship between force and depth of penetration into a 









0 10 20 40 50 30 
Depth of penetration (mm) 
Compaction stresses (Pa) :N 6920; A 3460; 0 
1730; 
865; 0 432. 
Figure 6.6.3 Relationship between force and depth of penetration into a 
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Depth of Penetration (mm) 
Compaction stresses (Pa): 0 6920; A 3460; 9 1730; 
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Figure 6.6.4 Relationship between force and depth of penetration into a 










0 10 20 30 
Depth of penetration (mm) 
Compaction stresses (Pa): 0 6920; A 3460; 
9 1730; * 865. 
50 
Figure 6.6.5 Relationship between force and depth of penetration into a 




All of the penetration force versus depth curves exhibit the typical 
parabolic shape. As expected, the force required to Penetrate the 
powder bed increases as the force of compaction applied to the powder 
bed increases. This increase is more significant with the samples of 
nedocromil sodium and kaolin compared with the lactose and Starch 
1500 samples. 
The value of the unconfined compression stress was calculated 
using equation 6.2.4 with af, =1.4 [1491. The derived value for the 
unconfined compression stress showed very little variation over the 
replicate measurements at penetration depths greater than 10 mm. 
This can be seen in Figures 6.7.1 to 6.7.5. The error bars represent the 
standard deviation of the data. 
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Nedocromil sodium batch 5BI 
Jý 
1/ (penetration depth)2 (M- 
Compaction stress (Pa) : --0- 6920; A 3460; 
0-- 1730; 0- 865; 0 432. 
Figure 6.7.1 Relationship between the derived force of cohesion and the reciprocal of 
the square of the depth of penetration into a nedocromil sodium batch 5B I powder 
bed compressed with different loads 
Nedocromil sodium batch 2002B1 
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Figure 6.7.2 Relationship between the derived force of cohesion and the reciprocal of 
the square of the depth of penetration into a nedocromil sodium batch 2002B I 
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Figure 6.7.3 Relationship between the derived force of cohesion and the reciprocal of 
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Figure 6.7.4 Relationship between the derived force of cohesion and the reciprocal of 
the square of the depth of penetration into a kaolin powder bed compressed with 
different loads 
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Compaction stresses (Pa): 6920; --()- 3460; 
0- 1730; 0 865. 
1000000 
Figure 6.7.5 Relationship between the derived force of cohesion and the reciprocal of 
the square of the depth of penetration into a starch 1500 powder bed compressed 
with different loads 
The derived values for the force of cohesion at penetration depths 
greater than 10 mm, and the respective coefficient of variation are 
shown in Table 6.7.1. 
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Com paction stress 
6920 Pa 1 3460 Pa J 1730 Pa 1 865 Pa 432 Pa 
Nedocromil sodium Bat ch 5BI 
F. (Pa) 1951.8 1144.9 571.7 371.4 182. 
C. V. (%) 14.2 8.1 12.5 13.0 13.1 
Nedocromil sodium Batch 2002 BI I 
F, (Pa) 2658.9 1171.6 580.8 380.5 206.4 
C-V- (%) 8.8 9.6 8.3 8.6 15.3 
Lactose 
F,, (Pa) 568.3 442.7 340.0 237.4 187.5 
C-V- M) 16.4 13.3 15.6 18.9 18.1 
Kaolin 
F,, (Pa) 1975.4 1069.1 566.3 390.7 ý 217.3 
C. V- M 8.3 8.0 36.2 9.9 21.3 
Starch 1500 
F, (Pa) 588.3 455.1 380.4 202.5 not 
C. V. M) 20.9 17.1' 12.7 16.0 available 
Table 6.7.1 Derived values for the force of cohesion 
As expected, the increase in the magnitude of the compaction 
procedure increases the unconfined compression stress within the 
powder bed. This is observed at all penetration depths, and is a 
reflection of the increased cohesive interactions within the powder bed 
due to the compaction procedure. 
During the compaction procedure the volume of the powder bed 
is reduced. The rearrangement of the particles in the powder bed forms 
a less porous structure. This is achieved by the particles sliding past 
each other and coming into closer contact. The magnitude of the 
attractive forces which e)dst within the powder bed is dependent upon 
the interparticulate distance. Therefore as the compaction load 
increases the resulting decrease in the interparticulate distances within 
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the powder bed is reflected by the increase of the unconfined 
compression stress. 
The relationships between the applied compaction stress and the 
derived measure of the cohesive interaction within the powder bed are 
shown in Figure 6.7.6. 
Relationship between unconfined compression stress 
and compaction stress for rive pharmaceutical powders 
III 
2000 4000 6000 
Compaction stress (Pa) 
Batch 2002B1 
Nedocromil sodium 
Batch 5B I 
8000 







The magnitude of this measure of cohesive interaction at low 
compaction stresses is very similar for each of the five pharmaceutical 
powders investigated. Deviations in the behaviour due to the powder 
sample become apparent at compaction stresses in excess of 275 Pa. 
The cohesive interactions within the nedocromil sodium and kaolin 
powder beds increase In magnitude considerably more than those 
exhibited by the lactose and starch samples. This is a result of the 
particle size of the powder samples. As observed in section 2.2 particles 
of nedocromil, sodium and kaolin have particle sizes ranging from 
0.5, um to 3, um, whilst lactose and starch both have larger particles in 
the range of 50, um to 90 ym. 
At very small depths of penetration the derived magnitude of the 
unconfined compression stress tends to decrease for samples of lactose 
and kaolin, but increases for the nedocromil sodium samples. This 
suggests that the load is transmitted through the powder bed more 
effectively by the lactose and kaolin samples when compared with the 
samples of nedocromil sodium. 
6.8 Conclusion 
Using the cone penetrometry technique it is possible to 
differentiate between cohesive and free-flowing powders. This can be 
achieved by evaluating the unconfined compression stress within the 




The technique, however, does not have the sensitivity capability 
to evaluate the cohesive interactions between particles in a powder bed 
without preparing the bed by compaction. 
At high bed compaction forces differentiation between the 
cohesive natures of the powders tested is possible. However, 
extrapolation to zero load, to yield the magnitude of the cohesive 
interaction within the uncompressed powder mass, resulted in values 
which could not differentiate between the fundamental cohesion 
properties of the powders under test. Thus a potentially useful test 
appears, unfortunately, to be insensitive to the subtle differences in 
powder cohesion which manifest themselves in significant differences in 





evaluation of powder 
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As reported in Chapter 3 binary Interactive mixes involve both 
adhesive and cohesive interactions, creating a powder mix which has 
characteristics of both an interactive mix and a random mix.. 
The aim of this chapter was to encourage the presence of 
cohesive aggregates within the binary powder mix, and assess the 
structure of such mixes in order to elucidate whether the structure of 
the mix would move towards the structure of an interactive mix. 
This was done by preparing cohesive pellets of drug prior to 
mixing, by a tumbling method. The determination of the degree of 
adhesive and cohesive interactions within the powder mix was carried 
out as described in Chapters 3 and 4 respectively. 
7.2 Introduction 
Interactive powder mixes are formed when micronised powder 
particles adhere to the surface of larger crystals [531. In powder mixes 
for inhalation therapy the micronised powder is the drug which is to be 
delivered to the lungs. 
Adhesion of single particles of the drug to the surface of lactose 
particles has previously been encouraged by sieving the drug before 
mixing. During the mixing process adhesive interactions between the 
drug and particles of lactose have been established. Cohesive 
interactions were responsible for the formation of smaller drug 
aggregates within the powder mix. The structure of the binary powder 
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nux thus created was such that some aggregates were adhered to the 
surface of the lactose particles, whilst others were non-interacting. The 
presence of non-interacting aggregates and lactose particles in the mix 
is analogous to a random powder mix as described by Lacey [ 45 1. 
In contrast to encouraging adhesion during the formation of 
binary interactive mixes by sieving the drug species prior to mixing, 
cohesion can be encouraged. This can be carried out by the preparation 
of cohesive drug aggregates. These can then be mixed with the lactose 
particles to form a binary mix. If such a system behaves as a random 
mixture no interparticulate interactions will occur. The homogeneity of 
a truly random mix of such a system can be determined by the Stange- 
Poole equation [811. This determines the standard deviation of the 
sample composition for the best possible mix, as shown in 
equation 7.2.1. 




Ma I Mb 
(equation 7.2.1) 
standard deviation of the sample composition as a 
proportion of the sample mass M 
mean proportion by mass of constituents A and B 
per sample 
representative mean particle mass of A and B 
constant sample mass (dose size) M= 
In contrast to this, adhesion/ cohesion competition may take 
place. Adhesive interactions between the drug and carrier species may 
create a mix which tends towards the structure of an interactive mix. 
Such a powder mix would contain interactive units composed of drug 
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particles adhered to the surface of the carrier particle. As discussed in 
Chapter 3, the best possible interactive mix can be described by the 
coeffIcient of variation (%) derived from the Poisson equation, shown in 
equation 7.2.2 [861. 
CR = 
100 (equation 7.2.2) 
rG 
Where 
In = representative mean particle mass 





Micronised material has been observed to form spherical 
aggregates when subjected to a tumbling action [ 1501. This procedure 
was investigated and optimised to prepare aggregates of nedocromil 
sodium. These aggregates were mixed with particles of cc-lactose 
monohydrate. The quality of these mixes was determined by assessing 
the homogeneity. Image analysis and scanning electron microscopy 
were used to visualise the structure of the mixes. 
7.4 Methods 
7.4.1 Preparation of drug, aggregates 
About 25 g of nedocromil sodium directly from the stock bottle 
was placed into a clean dry Erweka copper coating pan type DK3. The 
internal diameter of the pan was 375 nun, with a 19 litre capacity. The 
tumbling cycle shown below was followed. 
Step 
number 
Speed number Revolutions 
per second (Hz) 
Time (seconds) 
1 1 0.20 60 
2 2 0.27 60 
3 3 0.42 120 
4 2 0.27 60 
Table 7.4.1 Cohesive aggregate formation cycle 
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Subsequent to tumbling the prepared pellet batch was sieved 
using an Endecotts vibratory sieve shaker, model EVPl. The size 
fraction 180, um to 250 ym was collected. 
7.4.2 Mixing pellets 
7.4.2. a Materials 
Material Batch Aggregate sieve 
fraction 
Nedocromil sodium 5B1 180, um to 250, um 
a-lactose 22301 63, um to 90, um 
monohydrate 
Table 7.4.2 Powder samples 
7.4.2b Method 
Drug and lactose samples were weighed using a Mettler AT261 
balance. The quantity of each powder mix, 50 g and 25 g for 4 %w/w 
and 40 %w/w respectively, allowed a 50 % void space within the mixing 
vessel. 
A specially constructed stainless steel mixing cylinder was used 
to prepare the mixes. Curved internal joints replacing the 90' angles 
reduced the dead space in the vessel. The capacity of the vessel was 
160 CM3. 
The weighed samples were transferred to the mixing vessel and 
were mixed for 5 minutes using a Turbula mixer (T2C, W. A. Bachofen, 
Switzerland) set at 90 revolutions per minute (1.5 Hz). The vessel was 
then removed ftom the mixer and gently tapped in order to dislodge any 
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mix which had become adhered to the vertices of the vessel. This was 
followed by another 5 minute mbdng time at the same settings. 
7.4.3 Homogeneity testing 
The quality of the mixes was assessed by determining the 
homogeneity. Samples of the dose size, 25 mg, were taken from the 
niix. These samples were dissolved in deionised water and immediately 
assayed for drug content by UN spectroscopy as detailed in section 
2.11. 
7.4.4 Image analysis 
Image analysis was employed in order to identif y the structure of 
the drug aggregates. A Zeiss A)d6skop microscope was used, the images 
being produced using a Mitsubishi colour video copy processor 
(CP 100B). 
7.4.5 Scanning electron microscopy 
Samples of powder mixes were analysed using an International 
Scientific Instruments DS130 scanning electron microscope, as 
described in section 2.3. The following samples were analysed: 
1.4 %w/w nedocromil sodium pellets/lactose mix; 
2.40 %w/w nedocromil sodium pellets/lactose mix; 
3. Inhaler residue (as described in section 4.7.2) from 4 %w/w 
nedocromil sodium pellets/lactose mix; 
4. Inhaler residue (as described in section 4.7.2) from 40 %w/w 
nedocromil sodium pellets/lactose mix. 
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7.4.6 Powder mix residue 
The large value obtained for the sample coefficient of variation 
indicated that quantitative deposition testing using the multi-stage 
liquid impinger apparatus would incur large errors. The testing 
procedure was carried out, however, in order to collect the particles 
which remain in the cyclone chamber of the device after the inhalation 
cycle. 
7.4.6a Materials 
Analysis of the powder mixes containing 4 %w/w and 40 %w/w 
nedocromil sodium, prepared fýom drug aggregates was carried out. 
7.4.6b Method 
The in vitro inhalation testing procedure, detailed in Chapter 
Three was carried out. The powder which remained in the cyclone 
chamber was collected after each inhalation cycle. This residue powder 
was analysed using image analysis and scanning electron microscopy, 
as described in section 3.5.3. 
7.5 Results 
7.5.1 Analysis of drug aggregates 
As shown in the photomicrograph, Figure 7.5.1, the aggregates 
have a spherical shape. Image analysis confirmed that the diameter of 





19 A Ar 
Figure 7.5.1 Nedocromil sodium pellets. Magnification x 63. 
The image shows small drug aggregates attached to the surface of 
these aggregates. These are very similar to the surface held aggregates 
seen in the interactive mixes of nedocromil sodium and lactose, 
observed in Figures 3.6.4 to 3.6.8. 
The average aggregate mass was determined by assaying a known 
number of aggregates. The assay procedure was carried out as 
described in section 2.11. The mass of a single nedocromil sodium 








7.5.2 Homogeneity testing of the powder mix 
4% w/w aggregate mix 
123456789 10 
Sample number 
Figure 7.5.2 Assay results for 4 %w/w drug mix of nedocromil sodium 
aggregates with lactose 
Theoretical Drug content Standard Drug content by 
hydrated drug coefficient of deviation (mg) assay 
content variation M W/W) 
M W/W) 
L 4.0 7.71 0.077 4.003 
Table 7.5.1. Assay results for 4 %w/w drug mix of nedocromil, sodium 
aggregates with lactose 
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Figure 7.5.3. Assay results for 40 %w/w drug mix of nedocromil sodium 
aggregates with lactose 
Theoretical Drug content Standard Drug content by 
hydrated drug coefficient of deviation (mg) assay 
content variation M W/W) 
M W/W) (%) 
40 7.33 0.668 36.41 
Table 7.5.2 Assay results for 40 %w/w drug mix of nedocromil sodium 
aggregates with lactose 
The theoretical values for the standard deviation of drug content 
per sample can be calculated for the best possible random m ix, using 
the Stange-Poole equation (equation 7.2.1). These values for the 
theoretical best possible mix of nedocromil sodium aggregates (a) with 
lactose (b) are shown in Table 7.5.3.. 
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Table 7.5.3 Homogeneity values calculated using the Stange-Poole 
equation for powder mixes of nedocromil sodium aggregates with 
lactose 
Comparison of the experimental values for the sample coefficient 
of variation with the values determined theoretically show that the best 
attainable random mix has not been prepared. The theoretical values 
for the sample coefflcient of variation for the best possible interactive 
mix, as described by Egermann [861 (equation 3.2.5. ) are shown in 
Table 7.5.4. 
4.0 %w/w drug 40 %w/w drug 
content content 
Coefflcient of variation 0.013 0.004 
M) I I 
Table 7.5.4 Homogeneity values calculated using the Poisson-derived 
equation for powder mixes of nedocromil sodium with lactose 
Comparison of the experimental values for the sample coefficient 
of variation with the values determined theoretically show that the best 
attainable interactive mix has not been prepared. Therefore, the sample 
variation of binary mixes prepared with particles of lactose and 
nedocromil sodium aggregates conformed neither to that of the best 
possible random mix, nor the best possible interactive mix. 
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7.5.3 Image analysis of powder mixes 
Photomicrographs were obtained for the mixes of nedocromil 
sodium aggregates with lactose at drug concentrations 4 %w/w and 
40 %w/w. These are reproduced in Figures 7.5.2 and 7.5.3. 
Figure 7.5.2 Nedocromil sodium aggregate 4 %w/w /lactose powder 




Figure 7.5.3 Nedocromil sodium aggregate 40 %w/w /lactose powder 
mix. Magnification x 63. 
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Particles of lactose in both of the powder mixes have small 
aggregates of the drug associated with their surface. 
These surface held 
aggregates are more abundant in the higher concentration mix. 
As seen with the interactive mixes using pre-screened drug 
(Figures 3.6.20 and 3.6.21), the aggregates are attached to the lactose 
particle via a small number of anchor particles. These small aggregates 
can also be seen on the surface of the drug pellets in 
the mix. 
7.5.4 Scanning electron microscopy of powder mix 
Photornicrographs of the 4 %w/w and 40 %w/w powder 
blends 
are reproduced in Figures 7.5.4 to 7.5.7. 
Figure 7.5.4 Scanning electron micrograph of nedocromil 
sodium 
aggregate /lactose 4 %w/w powder mix with 
lactose. 
Non-adhered pellet. Picture number 1956. 
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Figure 7.5.5 Scanning electron micrograph of nedocromil sodium 
aggregate/ lactose 4 %w/w powder mix with 
lactose. Lactose particles. 
Picture number 1957. 
Figure 7.5.6 Scanning electron micrograph of nedocromil 
sodium 
aggregate /lactose 40 %w/w powder mix with 
lactose. Non-adhered 
pellet. Picture number 1987. 
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Figure 7.5.7 Scanning electron micrograph of nedocromil sodium 
aggregate /lactose 40 %w/w powder mix. Lactose particles. Picture 
number 1997. 
Small adhered aggregates are present in both of the powder 
mixes, as shown in the photomicrographs. These small aggregates are 
present both on the surfaces of the lactose particles and the surface of 
the larger aggregates. The size of these small aggregates is independent 
of the drug load, but the number is proportional to the drug load. 
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7.5.5 Scanning electron analysis of the mix residue 
Photornicrographs of the powder residue, collected after the 
inspiration cycle, are reproduced in Figures 7.5.8 and 7.5.9. 
Figure 7.5.8 Scanning electron micrograph of nedocromil sodium aggregate/ 
lactose 
powder residue from 4 %w/w drug mix after inhalation. 
Picture number 1976. 
Figure 7.5.9 Scanning electron micrograph of nedocromil sodium 
aggregate/ lactose 
powder residue from 40 %w /w drug mLx after 
inhalation. Picture number 20 10. 
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Surface held aggregates are no longer present in the powder 
residue from the lower drug load mix. This is in contrast to the residue 
from the 40 %w/w mix which retained some surface held aggregates 
throughout the inhalation cycle. 
Further magnification, Figure 7.5.10, of the surface of a lactose 
particle retained from the 4 %w/w powder mix shows the very fine drug 
particles whic 
Figure 7.5.10 Scanning electron micrograph of nedocromil sodium 
aggregate/ lactose powder residue from 4 %w/w drug mix after 
inhalation. Picture number 1980. 
The structure of the aggregate mixes deviates from the random 
behaviour of a binary mix due to adhesive interactions between 
particles of drug and lactose. This is reflected in the poor homogeneity 
exhibited by the mixes when compared with the best possible mix. The 
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structure of the mix tends towards an interactive mix due to the surface 
held particles of drug. However, the incomplete distribution of the drug 
from the aggregates onto the surface of the lactose prevents the best 
possible interactive powder mix being formed. A proportion of the non- 
interacting drug aggregates remain after the mixing process has been 
carried out. Therefore the powder mixes prepared by mixing lactose 
particles with aggregates of drug have a structure which, due to 
adhesive and cohesive interactions competing for particles of drug, 
combines the structures of random powder mixes and interactive 
powder mixes. 
7.7 Conclusion 
A method has been developed in order to prepare drug aggregates 
of a narrow size fraction. These were mixed with particles of lactose to 
create a random powder mix. The structure of this mix when viewed 
using scanning electron microscopy, deviated from that of a random 
mix due to adhesive interactions existing between the drug species and 
the carrier species. These adhesive interactions caused drug to be 
removed from the aggregates and become associated with the surface of 
the lactose particles. This process did not continue to completion, and 
so the structure of the powder mix was a combination of drug adhered 
to the surface of the lactose particles, and aggregates of drug which 
were not interacting with the particles of lactose. 
The structure of the mix prepared from samples which encourage 
the formation of a random mixture of particles did not correspond to a 
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true random distribution. Cohesive and adhesive interactions between 
the two powder species created a combined structure of an interactive 






Mbdng very small sized drug particles with larger carrier particles 
theoretically produces an interactive powder mix in which the drug 
particles adhere to the surface of the carrier. Mbdng two particle 
species which are similar in terms of size and density theoretically 
produces a random type of powder mix. 
The structure of binary powder mixes prepared for inhalation 
therapy reflect neither an interactive nor a random type of mix. 
Theoretical interactive powder mixes assume complete adhesion 
of the smaller particle species to the surface of the carrier to complete a 
monolayer coverage of the larger particle. This assumes adhesive 
interactions take place over the whole surface of the carrier particle, 
and neglects any cohesive, drug-drug, particle interactions. 
Theoretical binary random powder mixes describes a random 
distribution of two species of powder particle within the powder bed. 
This assumes that adhesive interactions between the species do not 
take place. 
The real binary powder mixes combined the adhesive element of 
interactive mixes with the non-interacting element of random mixes. 
The interactive units of the real mixes are composed of a particle 
of lactose with associated particles of drug. This drug is adhered either 
as individual particles or as small cohesive aggregates. Non-interacting 
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aggregates of drug are also present in the mix, depending upon the 
drugload. 
This is the structure for binary powder mixes regardless of the 
method of the drug preparation. Sieving the drug in order to encourage 
adhesion and preparing drug aggregates in order to encourage a 
random mix results in a similar structure. 
The structure of the mix is due to both adhesive and cohesive 
interactions between the drug and carrier particles, and the drug-drug 
particles respectively. 
Adhesive interactions do not take place over the whole surface of 
the particle of lactose. Specific areas appear to be preferential points for 
adhesion. These specific areas are identified by the examination of 
particles which remain in the inhaler device after the inspiration cycle. 
The number of single particles associated with the surface of a carrier 
particle appears to be finite. 
Regardless of the drug preparation prior to mixing, drug particles 
are adhered as either single entities or small clusters. These small 
clusters are associated to the particle of lactose via small anchor 
particles, making the adhesive interaction. The clusters are held 
together by the cohesive forces which act within the aggregate. 
The mechanism of formation of these surface held aggregates 
may either be at the adhesive site, or before adhesion takes place. An 
initial adhered particle may be the focus of cohesive interactions of 
more drug particles to form a small drug cluster. This is similar to the 
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mechanism suggested by Stephenson [671 for the formation of an 
interactive mix. An alternative mechanism may be that the small drug 
clusters are created within the powder mix and adhere onto the surface 
of the carrier particle. Because of their small size, the drug particles 
have a correspondingly high surface energy. Reduction of the surface 
free energy is the favourable result of aggregate formation. If created 
within the mix, these aggregates come into contact either with an 
adhesive site on the surface of the carrier particle, or other small 
aggregates. The energy supplied by the mixer may be responsible for 
removing surface held aggregates from the particles of lactose, leaving 
single surface held particles of drug. 
When the drug load is high, non-interacting aggregates of drug 
are formed, but not at the expense of the surface held drug clusters. 
The formation of these larger drug aggregates coincides with the 
plateau of the % w/w drug remaining adhered to carrier particles after 
the inhalation cycle. This may be due to the number of sites for 
adhesion of drug to the carrier being saturated. This would encourage 
the non-adhered small clusters to cohere, forming larger drug 
aggregates. Alternatively, the large drug load, and correspondingly large 
number of drug particles may readily cohere to form drug aggregates 
which are too large to adhere to the carrier particles. These may then be 
in competition with the lactose particles to be associated with the 
smaller clusters of drug. These small drug clusters may transfer from 
the surface of the lactose particles to the surface of the drug aggregates 




Drug particles are removed from prepared drug aggregates to 
form surface held aggregates of drug on the surface of the carrier. The 
mechanism for this, as above, may be removal of single drug particles 
from the aggregate to adhere to the lactose, or cohere to drug particles 
already adhered. Alternatively, these small clusters of drug may form 
on the surface of the aggregate. Small clusters of drug were observed on 
the surface of the aggregates prior to mixing. These may then transfer 
to the lactose particles, or remain associated with the drug aggregate 
depending upon the magnitudes of the adhesive and cohesive 
interactions. 
These surface held aggregates appear to be the source of the drug 
from the powder mix which travels to the lower stages of the multi- 
stage liquid impinger apparatus. These clusters of drug appear either 
adhered to the particles of lactose, or to the surface of non-interacting 
drug aggregates. 
The creation of these larger drug aggregates provides more 
surface area in the powder mix with which the smaller drug clusters 
can be associated. Therefore, although the aggregate fraction of the 
powder mix increases due to the formation of non-dispersing drug 
aggregates, the number of dispersing, surface held aggregates also 
increases. The proportions of drug presented as respirable fraction and 
aggregate fraction, once this structure of the powder mix has been 
established, tends to be constant. 
At a high drug load the formation of drug aggregates from sieved 
powder during the process of mixing led to a poor homogeneity of the 
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powder mix. The system in this case tended towards cohesive 
interactions between the particles of drug in order to form these 
aggregates. When the aggregates were prepared in a controlled way to 
obtain a specific size fraction, the mix presented a better value for 
homogeneity. However, when the system tended towards adhesive 
interactions, at low drug loads, mbdng with prepared drug aggregates 
hinders the formation of interactive units. The preparation of the drug 
to encourage adhesion of small particles results in the mix with a better 
homogeneity. 
Drug concentration Sieved drug. Sample Drug as aggregates. 
(%w/w) coefficient of variation Sample coefficient of 
M) variation M) 
4.0 0.750 7.710 
40.0 10.266 7.336 
The structure of the binary mixes was slightly different according 
to the drug species used. Particles of nedocromil sodium and sodium 
cromoglycate differed only slightly with respect to physical 
characteristics such as size, shape and density. The particles of 
nedocromil sodium in the mix tended to display a more cohesive nature 
than the particles of sodium cromoglycate. However, when comparing 
the performance of the formulations in the multi-stage liquid impinger, 
their behaviour was very similar. 
The mixes using a smaller sized drug particle were prepared at 
drug concentrations which contained the same number of drug 
particles as the mixes of the larger drug species. Poor homogeneity due 
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to non-interacting aggregate formation and segregation occurred at a 
much lower drug concentration than observed with the mixes 
containing larger drug particles. However, when comparing the 
performances of the same number concentration mixes, the mixes 
containing the smaller sized particles perform better as an inhalation 
formulation. At low drug concentrations, the very small proportion of 
the dose recovered as the aggregate fraction, and the good homogeneity 
of the mix suggests that the drug interactive units formed release the 
drug as small particles rather than aggregates. The photomicrographs 
of these units have shown that the drug is adhered as single particles 
and small drug clusters. Therefore, the drug clusters from these mixes 
easily deaggregate to deliver a large proportion of drug to the lower 
stages of the impinger. 
In conclusion, drug delivered from binary powder mixes of a drug 
with carrier particles aims to travel to the pulmonary sites of action in 
order to exert a local pharmacological effect. The behaviour of these 
particles within the powder mix determines whether or not this result is 
achieved. 
It has been determined that due to both cohesive and adhesive 
interactions taking place between the drug and drug/carrier particles 
respectively, the drug particles may be located within a number of 
structures. It has been elucidated that drug particles with the potential 




Having determined the relationship between binary powder mix 
structure and drug delivery performance, investigation of the 
magnitude of particle interactions with a view to optimising the 
structure of the mix for drug delivery led to the development of two 
techniques. The insensitivity of the techniques suggests that binary 
powder blend optimisation will result from the application of more 
sensitive surface energy analysis of powder particles. 
In conclusion, this work has elucidated that binary powder mixes 
of micronised drug or micronised drug pellets, with lactose particles, 
prepared in a tumbling-rotary type blender exhibit a structure which 
has characteristics of both interactive and random mixes. 
Methodologies developed in order to quantify the magnitude of 
the adhesion and cohesion within the powder blends did not have the 
sensitivity capability to determine these forces. 
The respirable fraction delivered from the powder blends 
originates from small cohesive aggregates which are associated with the 
surface of the lactose particles. 
There is a difference in the mix structure and the deposition 
characteristics of the drug from the blend for different drug species. 
There is a difference in deposition characteristics from a powder 
blend due to the drug load. 
When the drug load is low, the respirable fraction is high. As the 
drug load increases, so does the number of non-adhered aggregates, 
which increases the aggregate fraction of the dose and therefore 
decreases the respirable fraction. However, this stabilises as the non- 
adhered aggregates provide a surface onto which the small surface-held 
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